ClinicalTrials.gg
CompletedNCT00546871Updated May 19, 2021Results posted

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

A Phase 2/3 interventional study of Immune Globulin Intravenous (Human), 10% in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 9 sites in United States. Open to participants aged 24 Months and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
49
Allocation
Non-randomized
Ages
24 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
11th of 26
49 · median 45
Started
2007
the only one that year
Phase 2/3
3 of 27
none open now
Registered
6th of 27
by date
Lead sponsor
8 of 27
Baxalta now part of Shire

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 11th largest by enrollment of the 26 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2/3, and was the 6th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 24 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the tolerability of IGIV, 10% given subcutaneously and the pharmacokinetics of immunoglobulin G (IgG) following subcutaneous (SC) treatment with IGIV, 10% in subjects with primary immunodeficiency (PID) disorders.

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
04

Who can participate

Ages eligible
24 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from either the subject or the subject's legally acceptable representative prior to any study-related procedures and study product administration
  • Diagnosis of a PID disorder as defined by World Health Organization criteria (IUIS Scientific Committee, Primary immunodeficiency diseases. Report of an IUIS Scientific Committee. Clin Exp Immunol. 1999) for which the subject has been receiving a regular regimen of IV immunoglobulin infusions every 21 ± 3 days or 28 ± 3 days or a regular SC immunoglobulin treatment at 1 to 2 week intervals over a period of at least 3 months pre-study at a dose of 300-800 mg/kg BW/4 weeks
  • Subjects are aged 2 years or older
  • Subjects have a serum trough level of IgG > 4.5 g/L at the last documented determination
  • A negative serum pregnancy test for any female subject who is of
  • Female subjects of childbearing potential agree to practice measures for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Subjects positive at enrollment for one or more of the following: surface antigen (HBsAg), PCR for virus (HCV), PCR for (HIV) Type 1
  • Subjects with levels of alanine amino transferase () or aspartate amino transferase (AST) > 2.5 times the for the testing laboratory
  • Subjects with neutropenia (defined as an [ANC] \<= 500/mm3)
  • Subjects with serum creatinine levels greater than 1.5 times the upper limit of normal for age and gender
  • Subjects with a other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
  • Subjects with a history of thrombotic episodes (deep vein thrombosis, myocardial infarction, cerebrovascular accident)
  • Subjects with abnormal protein loss (protein losing enteropathy, nephritic syndrome, severe lung disease)
  • Subjects with anemia that would preclude phlebotomy for laboratory studies
  • Subjects who received any blood or blood product other than an IGIV, SC immunoglobulin, immune serum globulin (ISG) preparation, or albumin within the 6 months prior to study enrollment
  • Subjects with an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV, SC immunoglobulin and/or ISG infusions
  • Subjects with IgA deficiency and known anti IgA antibodies
  • Subjects receiving antibiotic therapy for the treatment of infection within 7 days prior to enrollment
  • Subjects participating in another clinical study involving an product or device within 28 days prior to study enrollment
  • Subjects with bleeding disorders or who are on anti-coagulation therapy
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
49 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage

    Expressed as (AUC_SC/AUC_IV) \* 100

    Time frame: Week 12 (IV) and week 32 or 33 (SC)

  2. Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10%, in Participants Aged 2 to <12 Years.

    Administration of IGIV, 10%: - Part 1 = IV administration (IV) - Parts 2, 3a, 3b = SC administration (SC)

    Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visits 1, and 5 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; and at the end-of-study evaluation

  3. Percentage of Participants in Full Safety Data Set (FSDS) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

    Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

    Time frame: Throughout study (1 year and 9 months)

  4. Percentage of Participants Naïve to SC Administration of Immunoglobulins (SNSC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped.

    Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

    Time frame: Throughout study (1 year and 9 months)

  5. Percentage of Participants With Prior Experience With Subcutaneous Administration of Immunoglobulins (SESC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

    Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

    Time frame: Throughout study (1 year and 9 months)

  6. Percentage of Infusions in FSDS for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

    Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

    Time frame: Throughout study (1 year and 9 months)

  7. Percentage of Infusions in SNSC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

    Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

    Time frame: Throughout study (1 year and 9 months)

  8. Percentage of Infusions in SESC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

    Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

    Time frame: Throughout study (1 year and 9 months)

Secondary outcomes

  1. Study Part 1 (IV): Maximum Plasma Concentration (C-max)

    Maximal immune globulin concentration after infusion

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.

  2. Study Part 1 (IV): Minimum Plasma Concentration (C-min)

    Minimal immune globulin concentration after infusion

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.

  3. Study Part 1 (IV): Weight-adjusted Clearance

    Computed as weight-adjusted dose divided by total AUC

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.

  4. Study Part 1 (IV): Terminal Half-life

    Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50%during the terminal phase.

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.

  5. Study Part 2 (Subcutaneous (SC)): Maximum Plasma Concentration (C-max)

    Maximal immune globulin concentration after infusion

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  6. Study Part 2 (SC): Time to Maximum Immune Globulin Concentration (T-max)

    Time to reach C-max

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  7. Study Part 2 (SC): Minimum Plasma Concentration (C-min)

    Minimal immune globulin concentration after infusion

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  8. Study Part 2 (SC): Weight-adjusted Clearance

    Computed as weight-adjusted dose divided by total AUC

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  9. Study Part 3B: Maximum Plasma Concentration (C-max)

    Maximal immune globulin concentration after infusion

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  10. Study Part 3B: Time to Maximum Immune Globulin Concentration (T-max)

    Time to reach C-max

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  11. Study Part 3B: Minimum Plasma Concentration (C-min)

    Minimal immune globulin concentration after infusion

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  12. Study Part 3B: Area Under the Curve (AUC)

    The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Study Parts 1, 2 and 3b, AUC(0-τ) was standardized for the infusion intervals (3 or 4 weeks vs. 1 week).

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  13. Study Part 3B: Weight-adjusted Clearance

    Computed as weight-adjusted dose divided by total AUC

    Time frame: Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.

  14. Trough Levels of IgG After Administration of IGIV, 10%, in Participants 12 Years and Older

    Part 1: IgG trough levels measured at each IV infusion day (every 3rd or 4th week depending on schedule/frequency of participants for a total of 12 weeks) Part 2: IgG trough levels measured at weeks 1, 5 and 9 (of a total of 12 weeks) Part 3a: IgG trough levels measured at weeks 1 and 5 (of a total of 6 weeks) Part 3b: IgG trough levels measured at weeks 1, 5, 9 and 12 (of a total of 12 weeks)

    Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visits 1, and 5 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; and at the end-of-study evaluation

  15. Trough Levels of Antibody to Haemophilus Influenzae In All Study Participants

    Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.

    Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation

  16. Trough Levels of Antibody to Hepatitis B in All Study Participants

    Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.

    Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation

  17. Trough Levels of Antibody to Tetanus In All Study Participants

    Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.

    Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation

  18. Number of Anti-Measles Antibody Titers That Were Below or Above the Protective Titer Level

    Antibody Titers That Were Below or Above the Protective Titer Level of \>1:8 for IV and SC Treatment in Study Parts 1, 2, 3a and 3b. Participants had multiple anti-measles antibody titers measured during the study.

    Time frame: Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation

  19. Annual Infection Rates During Treatment

    Annual rate of all infections calculated using a Poisson model to account for different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with allowance for overdispersion by deviance method. Point estimates and likelihood-ratio based 95% confidence intervals were provided. Infections as included in analysis comprised all reported AEs that were coded to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of infections and infestations, described as an infection by investigator, or for which anti-infective medication was prescribed.

    Time frame: Throughout the study, 1 year and 9 months

  20. Annual Rate of Acute Serious Bacterial Infections During IV and SC Treatment (FSDS)

    Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with an allowance for overdispersion by the deviance method.

    Time frame: Throughout the study, 1 year and 9 months

  21. Rate of Temporally Associated AEs Per Infusion

    Rate of AEs per infusion defined as the total number of all AEs that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") divided by the total number of infusions.

    Time frame: During Infusion or Within 72 Hours of Completion of Infusions

  22. AEs Deemed/Judged to be Related by the Investigator

    Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug that occur at any time during the study divided by the total number of infusions.

    Time frame: Throughout the study period (1 year and 9 months)

  23. Frequency of Dose Adjustments (If IgG Trough Levels <4.5 g/L)

    Frequency of Dose Adjustments Based on IgG Trough Levels \<4.5 g/L IgG, if Any, for Each Study Part. Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.

    Time frame: Throughout the study period (1 year and 9 months)

  24. Proportion of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs

    Proportion of Participants Reporting 1 or More Moderate or Severe AEs That Begin During Infusion or Within 72 Hours of Completion of an Infusion.

    Time frame: During Infusion or Within 72 Hours of Completion of Infusions

  25. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)

    Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR

    Time frame: Throughout entire study (1 year and 9 months)

  26. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)

    Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.

    Time frame: Throughout entire study (1 year and 9 months)

  27. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC -All Ages)

    Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR

    Time frame: Throughout entire study (1 year and 9 months)

  28. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC- All Ages)

    Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.

    Time frame: Throughout entire study (1 year and 9 months)

  29. Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)

    Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR

    Time frame: Throughout entire study (1 year and 9 months)

  30. Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)

    Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.

    Time frame: Throughout entire study (1 year and 9 months)

  31. Percentage of Infusions Associated With ≥1 AE Related to the Study Drug

    Time frame: Throughout the study period (1 year and 9 months)

  32. Percentage of Infusions Associated With ≥1 AEs That Begin During Infusion or Within 72 Hours of Completion of Infusion

    Time frame: During Infusion or Within 72 Hours of Completion of Infusions

  33. Percentage of Infusions Associated With ≥1 AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.

    Time frame: During Infusion or Within 72 Hours of Completion of Infusions

  34. Percentage of Infusions Associated With ≥1 Systemic AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.

    Time frame: During Infusion or Within 72 Hours of Completion of Infusions

  35. Percentage of Infusions Associated With ≥1 Local AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.

    Time frame: During Infusion or Within 72 Hours of Completion of Infusions

07

Results

Posted Aug 23, 2012

Participant flow

Recruitment was conducted in the United States at 9 study sites.

Part 1 - IV Infusions of IGIV, PK
Participant flow — Part 1 - IV Infusions of IGIV, PK
Milestone2 to <12 Years12 Years and Older
Started1435
Completed1335
Not completed10
Withdrew: Withdrawal by subject10
Part 2 - Subcutaneous (SC) IGIV, PK
Participant flow — Part 2 - Subcutaneous (SC) IGIV, PK
Milestone2 to <12 Years12 Years and Older
Started1335
Completed1232
Not completed13
Withdrew: Withdrawal by subject12
Withdrew: Family emergency01
Part 3a- SC IGIV Adjusted Dose, PK Based
Participant flow — Part 3a- SC IGIV Adjusted Dose, PK Based
Milestone2 to <12 Years12 Years and Older
Started1232
Completed1232
Not completed00
Part 3b - SC IGIV 12 Weeks
Participant flow — Part 3b - SC IGIV 12 Weeks
Milestone2 to <12 Years12 Years and Older
Started1232
Completed1232
Not completed00
Study Extension Period
Participant flow — Study Extension Period
Milestone2 to <12 Years12 Years and Older
Started1026
Completed925
Not completed11
Withdrew: Protocol violation10
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryRatio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage

Expressed as (AUC_SC/AUC_IV) \* 100

Time frame:
Week 12 (IV) and week 32 or 33 (SC)
Reported as:
Number · percent
Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage
percentParticipants ≥12 Years Old With PK Data Part 1 and Part 3b
Ratio of Area Under the Concentration Curve (AUC 0-τ)/Week Following IV Administration to SC Administration of IGIV, 10% at an Adjusted/Individual Adapted Dose (Part 3b), Expressed as a Percentage95.2 (92.3 to 98.2)
PrimaryBioavailability (Trough Levels) of IgG After Administration of IGIV, 10%, in Participants Aged 2 to <12 Years.

Administration of IGIV, 10%: - Part 1 = IV administration (IV) - Parts 2, 3a, 3b = SC administration (SC)

Time frame:
Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visits 1, and 5 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; and at the end-of-study evaluation
Reported as:
Median · g/L
Bioavailability (Trough Levels) of IgG After Administration of IGIV, 10%, in Participants Aged 2 to <12 Years.
g/LParticipants Aged 2 to <12 Years
Part 1 (IV), Screening visit (n=14)11.400 (9.640 to 16.800)
Part 1 (IV), 3 week Interval, Visit 1 (n=5)10.100 (NA to NA)
Part 1 (IV), 3 week Interval, Visit 2 (n=4)11.500 (NA to NA)
Part 1 (IV), 3 week Interval, Visit 3 (n=5)10.600 (NA to NA)
Part 1 (IV), 3 week Interval, Visit 4 (n=5)10.100 (NA to NA)
Part 1 (IV), 3 week Interval, Visit 5 (n=5)10.800 (NA to NA)
Part 1 (IV), 4 week Interval, Visit 1 (n=7)9.640 (7.240 to 17.400)
Part 1 (IV), 4 week Interval, Visit 2 (n=9)10.000 (7.230 to 12.400)
Part 1 (IV), 4 week Interval, Visit 3 (n=7)9.080 (6.340 to 18.500)
Part 1 (IV), 4 week Interval, Visit 4 (n=8)10.500 (7.420 to 17.800)
Part 2 (SC), Visit 1 (n=12)13.650 (12.300 to 16.700)
Part 2 (SC), Visit 5 (n=12)12.800 (11.200 to 16.500)
Part 2 (SC), Visit 9 (n=12)13.600 (10.100 to 17.100)
Part 3a (SC), Visit 1 (n=11)11.200 (10.300 to 19.100)
Part 3a (SC), Visit 5 (n=11)12.200 (11.500 to 20.000)
Part 3b (SC), Visit 1 (n=12)11.500 (9.170 to 15.800)
Part 3b (SC), Visit 5 (n=12)12.600 (10.200 to 15.200)
Part 3b (SC), Visit 9 (n=12)12.800 (10.300 to 15.900)
End of Study (n=13)12.300 (8.570 to 18.000)
SecondaryStudy Part 1 (IV): Maximum Plasma Concentration (C-max)

Maximal immune globulin concentration after infusion

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · g/L
Study Part 1 (IV): Maximum Plasma Concentration (C-max)
g/L12 Years and Older
Study Part 1 (IV): Maximum Plasma Concentration (C-max)22.7 (21.0 to 25.0)
SecondaryStudy Part 1 (IV): Minimum Plasma Concentration (C-min)

Minimal immune globulin concentration after infusion

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · g/L
Study Part 1 (IV): Minimum Plasma Concentration (C-min)
g/L12 Years and Older
Study Part 1 (IV): Minimum Plasma Concentration (C-min)10.1 (9.4 to 12.4)
SecondaryStudy Part 1 (IV): Weight-adjusted Clearance

Computed as weight-adjusted dose divided by total AUC

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · mL/kg/day
Study Part 1 (IV): Weight-adjusted Clearance
mL/kg/day12 Years and Older
Study Part 1 (IV): Weight-adjusted Clearance1.36 (1.23 to 1.42)
SecondaryStudy Part 1 (IV): Terminal Half-life

Computed from the regression slope in the terminal phase of the model (the slope is biphasic). Terminal half life is the time it takes for the plasma concentration or the amount of immunoglobulin in the body to be reduced by 50%during the terminal phase.

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #3 starts) up to 28 days (+/-2 days) post-infusion.
Reported as:
Median · days
Study Part 1 (IV): Terminal Half-life
days12 Years and Older
Study Part 1 (IV): Terminal Half-life33.1 (28.7 to 41.4)
SecondaryStudy Part 2 (Subcutaneous (SC)): Maximum Plasma Concentration (C-max)

Maximal immune globulin concentration after infusion

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · g/L
Study Part 2 (Subcutaneous (SC)): Maximum Plasma Concentration (C-max)
g/L12 Years and Older
Study Part 2 (Subcutaneous (SC)): Maximum Plasma Concentration (C-max)14.5 (12.3 to 16.4)
SecondaryStudy Part 2 (SC): Time to Maximum Immune Globulin Concentration (T-max)

Time to reach C-max

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · days
Study Part 2 (SC): Time to Maximum Immune Globulin Concentration (T-max)
days12 Years and Older
Study Part 2 (SC): Time to Maximum Immune Globulin Concentration (T-max)4.8 (3.0 to 4.9)
SecondaryStudy Part 2 (SC): Minimum Plasma Concentration (C-min)

Minimal immune globulin concentration after infusion

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · g/L
Study Part 2 (SC): Minimum Plasma Concentration (C-min)
g/L12 Years and Older
Study Part 2 (SC): Minimum Plasma Concentration (C-min)12.5 (11.3 to 14.2)
SecondaryStudy Part 2 (SC): Weight-adjusted Clearance

Computed as weight-adjusted dose divided by total AUC

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · mL/kg/day
Study Part 2 (SC): Weight-adjusted Clearance
mL/kg/day12 Years and Older
Study Part 2 (SC): Weight-adjusted Clearance1.86 (1.61 to 2.04)
SecondaryStudy Part 3B: Maximum Plasma Concentration (C-max)

Maximal immune globulin concentration after infusion

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · g/L
Study Part 3B: Maximum Plasma Concentration (C-max)
g/L12 Years and Older
Study Part 3B: Maximum Plasma Concentration (C-max)14.1 (12.5 to 16.3)
SecondaryStudy Part 3B: Time to Maximum Immune Globulin Concentration (T-max)

Time to reach C-max

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · days
Study Part 3B: Time to Maximum Immune Globulin Concentration (T-max)
days12 Years and Older
Study Part 3B: Time to Maximum Immune Globulin Concentration (T-max)2.9 (1.2 to 3.2)
SecondaryStudy Part 3B: Minimum Plasma Concentration (C-min)

Minimal immune globulin concentration after infusion

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · g/L
Study Part 3B: Minimum Plasma Concentration (C-min)
g/L12 Years and Older
Study Part 3B: Minimum Plasma Concentration (C-min)12.6 (10.6 to 14.0)
SecondaryStudy Part 3B: Area Under the Curve (AUC)

The AUC between adjacent infusions was calculated by the trapezoidal rule. Linear interpolation/extrapolation was used to calculate the AUC for the exact duration of the infusion intervals (21 or 28 days for IV administration and 7 days for SC administration). To allow for comparisons between Study Parts 1, 2 and 3b, AUC(0-τ) was standardized for the infusion intervals (3 or 4 weeks vs. 1 week).

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · g*days/L
Study Part 3B: Area Under the Curve (AUC)
g*days/L12 Years and Older
Study Part 3B: Area Under the Curve (AUC)94.6 (80.4 to 106.9)
SecondaryStudy Part 3B: Weight-adjusted Clearance

Computed as weight-adjusted dose divided by total AUC

Time frame:
Pharmacokinetic evaluations: 60 minutes pre-infusion (before infusion #8 starts) up to 7 days (+/-1 day) post-infusion.
Reported as:
Median · mL/kg/day
Study Part 3B: Weight-adjusted Clearance
mL/kg/day12 Years and Older
Study Part 3B: Weight-adjusted Clearance2.00 (1.84 to 2.12)
SecondaryTrough Levels of IgG After Administration of IGIV, 10%, in Participants 12 Years and Older

Part 1: IgG trough levels measured at each IV infusion day (every 3rd or 4th week depending on schedule/frequency of participants for a total of 12 weeks) Part 2: IgG trough levels measured at weeks 1, 5 and 9 (of a total of 12 weeks) Part 3a: IgG trough levels measured at weeks 1 and 5 (of a total of 6 weeks) Part 3b: IgG trough levels measured at weeks 1, 5, 9 and 12 (of a total of 12 weeks)

Time frame:
Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visits 1, and 5 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; and at the end-of-study evaluation
Reported as:
Median · g/L
Trough Levels of IgG After Administration of IGIV, 10%, in Participants 12 Years and Older
g/L12 Years and Older
Part 1, Screening visit (n=35)11.800 (10.300 to 13.000)
Part 1, 3 week Interval, Visit 1 (n=4)10.900 (NA to NA)
Part 1, 3 week Interval, Visit 2 (n=4)11.050 (NA to NA)
Part 1, 3 week Interval, Visit 3 (n=5)14.000 (NA to NA)
Part 1, 3 week Interval, Visit 4 (n=5)11.700 (NA to NA)
Part 1, 3 week Interval, Visit 5 (n=5)12.400 (NA to NA)
Part 1, 4 week Interval, Visit 1 (n=29)11.000 (10.000 to 12.300)
Part 1, 4 week Interval, Visit 2 (n=29)10.800 (9.650 to 12.500)
Part 1, 4 week Interval, Visit 3 (n=30)10.200 (9.480 to 12.600)
Part 1, 4 week Interval, Visit 4 (n=30)10.150 (9.480 to 12.200)
Part 2, Visit 1 (n=35)15.300 (14.800 to 17.100)
Part 2, Visit 5 (n=34)12.700 (11.600 to 15.200)
Part 2, Visit 9 (n=32)12.900 (11.800 to 14.800)
Part 3a, Visit 1 (n=32)12.850 (11.600 to 14.900)
Part 3a, Visit 5 (n=31)13.100 (11.400 to 15.100)
Part 3b, Visit 1 (n=31)12.900 (11.600 to 15.200)
Part 3b, Visit 5 (n=28)13.400 (11.000 to 14.600)
Part 3b, Visit 9 (n=31)13.600 (11.000 to 14.400)
End of Study (n=34)13.100 (11.300 to 14.400)
SecondaryTrough Levels of Antibody to Haemophilus Influenzae In All Study Participants

Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.

Time frame:
Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Reported as:
Median · µg/mL
Trough Levels of Antibody to Haemophilus Influenzae In All Study Participants
µg/mLAll Participants
Part 1, Screening visit (n=49)2.790 (2.300 to 3.240)
Part 1, 3 week Interval, Visit 1 (n=10)2.830 (2.020 to 4.350)
Part 1, 3 week Interval, Visit 2 (n=10)2.885 (1.910 to 4.310)
Part 1, 3 week Interval, Visit 3 (n=10)3.150 (2.030 to 3.950)
Part 1, 3 week Interval, Visit 4 (n=10)3.145 (0.820 to 4.040)
Part 1, 3 week Interval, Visit 5 (n=10)3.045 (1.650 to 4.140)
Part 1, 4 week Interval, Visit 1 (n=38)2.210 (1.860 to 2.480)
Part 1, 4 week Interval, Visit 2 (n=39)2.030 (1.680 to 2.780)
Part 1, 4 week Interval, Visit 3 (n=39)2.130 (1.750 to 2.670)
Part 1, 4 week Interval, Visit 4 (n=38)2.135 (2.020 to 2.610)
Part 2, Visit 1 (n=47)3.280 (3.000 to 3.860)
Part 2, Visit 5 (n=46)2.810 (2.360 to 3.080)
Part 2, Visit 9 (n=44)3.175 (2.530 to 3.470)
Part 3a, Visit 1 (n=44)2.840 (2.400 to 3.160)
Part 3b, Visit 1 (n=43)3.030 (2.610 to 3.500)
Part 3b, Visit 5 (n=41)3.070 (2.820 to 3.650)
Part 3b, Visit 9 (n=44)3.285 (2.780 to 3.870)
Extension, Visit 1 (n=36)2.940 (2.530 to 3.780)
End of Study (n=46)3.010 (2.660 to 3.690)
SecondaryTrough Levels of Antibody to Hepatitis B in All Study Participants

Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.

Time frame:
Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Reported as:
Median · mIU/mL
Trough Levels of Antibody to Hepatitis B in All Study Participants
mIU/mLAll Participants
Part 1, Screening visit (n=36)239.450 (180.000 to 293.300)
Part 1, 3 week Interval, Visit 1 (n=8)182.050 (139.500 to 789.000)
Part 1, 3 week Interval, Visit 2 (n=10)251.150 (208.600 to 311.900)
Part 1, 3 week Interval, Visit 3 (n=10)282.050 (231.900 to 333.900)
Part 1, 3 week Interval, Visit 4 (n=10)274.200 (223.100 to 460.700)
Part 1, 3 week Interval, Visit 5 (n=10)261.850 (233.900 to 292.400)
Part 1, 4 week Interval, Visit 1 (n=36)197.750 (135.600 to 242.200)
Part 1, 4 week Interval, Visit 2 (n=39)213.600 (191.000 to 282.500)
Part 1, 4 week Interval, Visit 3 (n=39)202.800 (172.200 to 262.600)
Part 1, 4 week Interval, Visit 4 (n=38)207.850 (183.800 to 265.800)
Part 2, Visit 1 (n=46)401.350 (380.800 to 482.200)
Part 2, Visit 5 (n=46)341.100 (301.700 to 364.700)
Part 2, Visit 9 (n=44)316.800 (282.800 to 367.900)
Part 3a, Visit 1 (n=44)318.450 (280.200 to 351.000)
Part 3b, Visit 1 (n=43)385.200 (304.300 to 454.300)
Part 3b, Visit 5 (n=41)314.100 (247.200 to 374.900)
Part 3b, Visit 9 (n=44)351.050 (292.000 to 412.200)
Extension, Visit 1 (n=36)328.750 (273.100 to 368.400)
End of Study (n=44)319.600 (297.000 to 372.400)
PrimaryPercentage of Participants in Full Safety Data Set (FSDS) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

Time frame:
Throughout study (1 year and 9 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants in Full Safety Data Set (FSDS) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Percentage of ParticipantsInfusion Rate Change - For Any ReasonInfusion Rate Change - For Tolerability/AE
Study Part 1 (IV) (n= 49)18.416.3
Study Part 2 (SC) (n= 47)29.84.3
Study Part 3A (SC) (n=44)15.92.3
Study Part 3B (SC) (n=44)13.62.3
Study Extension (SC) (n= 36)13.90.0
Study Part 2, 3A, 3B, Study Extension (n= 47)40.44.3
SecondaryTrough Levels of Antibody to Tetanus In All Study Participants

Trough levels for IV and SC Treatment in Study Parts 1, 2, 3a and 3b.

Time frame:
Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Reported as:
Median · IU/mL
Trough Levels of Antibody to Tetanus In All Study Participants
IU/mLAll Participants
Part 1, Screening visit (n=49)2.840 (2.500 to 3.660)
Part 1, 3 week Interval, Visit 1 (n=10)3.010 (1.740 to 3.640)
Part 1, 3 week Interval, Visit 2 (n=10)3.500 (1.970 to 4.640)
Part 1, 3 week Interval, Visit 3 (n=10)3.360 (2.180 to 4.540)
Part 1, 3 week Interval, Visit 4 (n=10)3.205 (1.810 to 5.030)
Part 1, 3 week Interval, Visit 5 (n=10)3.520 (2.230 to 4.220)
Part 1, 4 week Interval, Visit 1 (n=37)2.340 (1.980 to 2.830)
Part 1, 4 week Interval, Visit 2 (n=39)2.360 (1.880 to 2.760)
Part 1, 4 week Interval, Visit 3 (n=38)2.125 (1.890 to 2.680)
Part 1, 4 week Interval, Visit 4 (n=36)2.325 (1.910 to 2.800)
Part 2, Visit 1 (n=47)4.310 (3.890 to 5.050)
Part 2, Visit 5 (n=46)3.445 (2.920 to 4.030)
Part 2, Visit 9 (n=43)3.720 (3.090 to 4.160)
Part 3a, Visit 1 (n=44)3.090 (2.670 to 3.830)
Part 3b, Visit 1 (n=43)3.690 (3.210 to 4.220)
Part 3b, Visit 5 (n=41)3.410 (2.780 to 4.440)
Part 3b, Visit 9 (n=43)3.150 (2.920 to 3.920)
Extension, Visit 1 (n=36)3.355 (2.440 to 4.480)
End of Study (n=46)3.860 (3.150 to 5.000)
SecondaryNumber of Anti-Measles Antibody Titers That Were Below or Above the Protective Titer Level

Antibody Titers That Were Below or Above the Protective Titer Level of \>1:8 for IV and SC Treatment in Study Parts 1, 2, 3a and 3b. Participants had multiple anti-measles antibody titers measured during the study.

Time frame:
Baseline; at each 3 or 4-week study visit in Study Part 1; at Visits 1, 5, and 9 in Study Part 2; at Visit 1 in Study Part 3a; at Visits 1, 5, and 9 in Study Part 3b; at Visit 1 in the Study Extension Part; and at the end-of-study evaluation
Reported as:
Number · Antibody titers
Number of Anti-Measles Antibody Titers That Were Below or Above the Protective Titer Level
Antibody titersFull Safety Data Set
Anti-Measles Antibody Tests Below a Titer of >1:80
Anti-Measles Antibody Tests Above a Titer of >1:8654
SecondaryAnnual Infection Rates During Treatment

Annual rate of all infections calculated using a Poisson model to account for different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with allowance for overdispersion by deviance method. Point estimates and likelihood-ratio based 95% confidence intervals were provided. Infections as included in analysis comprised all reported AEs that were coded to the Medical Dictionary for Regulatory Activities (MedDRA) system organ class (SOC) of infections and infestations, described as an infection by investigator, or for which anti-infective medication was prescribed.

Time frame:
Throughout the study, 1 year and 9 months
Reported as:
Mean · Estimated infections per year
Annual Infection Rates During Treatment
Estimated infections per year2 to <12 Years12 Years and Older
Study Part 1 (IV)5.0 (2.3 to 9.3)5.2 (3.6 to 7.2)
Study Part 2 (SC)5.6 (2.7 to 10.0)4.1 (2.6 to 6.1)
Study Part 3A (SC)3.5 (1.4 to 7.1)4.6 (2.6 to 7.3)
Study Part 3B (SC)3.9 (1.6 to 7.8)3.8 (2.4 to 5.8)
Study Extension (SC)4.0 (2.4 to 6.2)3.8 (2.6 to 5.3)
Study Part 2, 3A, 3B, Study Extension (all SC)4.3 (2.8 to 6.4)4.0 (3.0 to 5.2)
SecondaryAnnual Rate of Acute Serious Bacterial Infections During IV and SC Treatment (FSDS)

Annual rate of validated acute serious bacterial infections was calculated using a Poisson model to account for the different lengths of observation per subject using SAS V9.1.3 procedure GENMOD with an allowance for overdispersion by the deviance method.

Time frame:
Throughout the study, 1 year and 9 months
Reported as:
Number · Estimated infections/year
Annual Rate of Acute Serious Bacterial Infections During IV and SC Treatment (FSDS)
Estimated infections/yearIV TreatmentAll SC Treatment Periods
Annual Rate of Acute Serious Bacterial Infections During IV and SC Treatment (FSDS)0.0000.067
Statistical analysis
  • All SC Treatment Periods · Poisson: 0.067
SecondaryRate of Temporally Associated AEs Per Infusion

Rate of AEs per infusion defined as the total number of all AEs that begin during infusion or within 72 hours of completion of an infusion ("temporally associated") divided by the total number of infusions.

Time frame:
During Infusion or Within 72 Hours of Completion of Infusions
Reported as:
Number · AEs per infusion
Rate of Temporally Associated AEs Per Infusion
AEs per infusionFSDSSNSCSESC
Study Part 1 (IV) (Units Analyzed N= 207, 162, 45)0.250.450.00
Study Part 2 (SC) (N = 595, 469, 126)0.080.130.08
Study Part 3a (SC) (N = 268, 206, 62)0.000.080.00
Study Part 3b (SC) (N = 538, 418, 120)0.080.080.00
Study Extension (SC) (N = 893, 664, 229)0.070.090.00
Total SC (N = 2294, 1757, 537)0.080.080.00
SecondaryAEs Deemed/Judged to be Related by the Investigator

Rate of related AEs defined as the total number of AEs determined by the investigator to be related to the study drug that occur at any time during the study divided by the total number of infusions.

Time frame:
Throughout the study period (1 year and 9 months)
Reported as:
Number · AEs per infusion
AEs Deemed/Judged to be Related by the Investigator
AEs per infusionFSDSSNSCSESC
Study Part 1 (IV) (Units Analyzed N= 207, 162, 45)0.000.250.00
Study Part 2 (SC) (N = 595, 469, 126)0.070.060.08
Study Part 3a (SC) (N = 268, 206, 62)0.000.000.00
Study Part 3b (SC) (N = 538, 418, 120)0.000.000.00
Study Extension (SC) (N = 893, 664, 229)0.000.030.00
Total SC (Study Parts 2, 3A, 3B, Study Extension)0.000.000.00
SecondaryFrequency of Dose Adjustments (If IgG Trough Levels <4.5 g/L)

Frequency of Dose Adjustments Based on IgG Trough Levels \<4.5 g/L IgG, if Any, for Each Study Part. Defined/calculated as the number of participants requiring dose adjustments divided by the number of participants, for each respective data set.

Time frame:
Throughout the study period (1 year and 9 months)
Reported as:
Number · ratio
Frequency of Dose Adjustments (If IgG Trough Levels <4.5 g/L)
ratioFSDSSNSCSESC
Study Part 1 (IV)0.000.000.00
Study Part 2 (SC)0.000.000.00
Study Part 3a (SC)0.000.000.00
Study Part 3b (SC)0.000.000.00
Study Extension (SC)0.000.000.00
Total SC (Study Parts 2, 3A, 3B, Study Extension)0.000.000.00
SecondaryProportion of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs

Proportion of Participants Reporting 1 or More Moderate or Severe AEs That Begin During Infusion or Within 72 Hours of Completion of an Infusion.

Time frame:
During Infusion or Within 72 Hours of Completion of Infusions
Reported as:
Number · Proportion of participants
Proportion of Participants Reporting ≥1 Temporally Associated Moderate or Severe AEs
Proportion of participantsFSDSSNSCSESC
Study Part 1 (IV)0.430.470.27
Study Part 2 (SC)0.360.440.09
Study Part 3a (SC)0.230.240.20
Study Part 3b (SC)0.360.380.30
Study Extension (SC)0.500.560.33
Total SC (Study Parts 2, 3A, 3B, Study Extension)0.660.750.36
PrimaryPercentage of Participants Naïve to SC Administration of Immunoglobulins (SNSC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped.

Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

Time frame:
Throughout study (1 year and 9 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Naïve to SC Administration of Immunoglobulins (SNSC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped.
Percentage of ParticipantsInfusion Rate Change - For Any ReasonInfusion Rate Change - For Tolerability/AE
Study Part 1 (IV) (n= 38)23.721.1
Study Part 2 (SC) (n= 36)33.35.6
Study Part 3A (SC) (n=34)20.62.9
Study Part 3B (SC) (n=34)17.62.9
Study Extension (SC) (n= 27)14.80.0
Study Part 2, 3A, 3B, Study Extension (n= 36)47.25.6
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)

Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR

Time frame:
Throughout entire study (1 year and 9 months)
Reported as:
Number · Adverse events
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)
Adverse eventsStudy Part 1, IV AdministrationStudy Part 2, SC AdministrationStudy Part 3a, SC AdministrationStudy Part 3b, SC AdministrationStudy Extension, SC AdministrationTotal SC (Parts 2, 3a, 3b, Extension)
Abdominal Discomfort- non-SAE, NR, Mild000033
Abdominal Distension-non-SAE, NR, Mild000077
Abdominal Distension-non-SAE, NR, Moderate000224
Abdominal Distension-non-SAE, R, Mild010102
Abdominal Distension-non-SAE, R, Moderate010001
Abdominal Pain-non-SAE, NR, Mild101012
Abdominal Pain-non-SAE, NR, Moderate000011
Abdominal Pain Upper-non-SAE, NR, Mild200066
Abdominal Pain Upper-non-SAE, NR, Moderate000022
Abdominal Pain Upper-non-SAE, R, Mild031004
Abdominal Tenderness-non-SAE, NR, Mild000101
Acne-non-SAE, NR, Mild010001
Acne-non-SAE, NR, Moderate000101
Acute Sinusitis-non-SAE, NR, Moderate010001
Addison's Disease-non-SAE, NR, Mild010001
Addison's Disease-non-SAE, NR, Moderate100000
Alopecia-non-SAE, NR, Mild100000
Ammonia Increased-non-SAE, NR, Mild010001
Animal Bite-non-SAE, NR, Moderate100000
Anorexia-non-SAE, NR, Moderate001001
Anxiety-non-SAE, NR, Mild000011
Aphthous Stomatitis-non-SAE, NR, Mild011024
Arthralgia-non-SAE, NR, Moderate031217
Arthralgia-non-SAE, NR, Severe000011
Arthralgia-non-SAE, R, Mild101001
Arthralgia-non-SAE, R, Moderate100000
Arthritis-non-SAE, NR, Moderate001001
Arthropod Bite-non-SAE, NR, Mild010012
Asthenia-non-SAE, NR, Mild000101
Asthenia-non-SAE, NR, Moderate001001
Asthma-non-SAE, NR, Mild000022
Asthma-non-SAE, NR, Moderate301135
Asthma-non-SAE, NR, Severe000101
Asthma-non-SAE, R, Mild010001
Asthma Exercise Induced-non-SAE, NR, Moderate010001
ADHD-non-SAE, NR, Mild010001
Back Pain-non-SAE, NR, Mild100202
Back Pain-non-SAE, NR, Moderate100202
Back Pain-non-SAE, R, Moderate100000
Biliary Tract Infection Bacterial-SAE, NR, Moderat010001
Blepharitis-non-SAE,NR, Mild001001
Blepharitis-non-SAE,NR, Moderate100000
B.P. Diastolic Decreased-non-SAE, R, Mild002002
Blood Pressure Increased-non-SAE, NR, Mild000202
Blood Pressure Increased-non-SAE, R, Mild000101
B.P. Systolic Increased-non-SAE, NR, Mild011002
B.P. Systolic Increased-non-SAE, NR, Moderate000101
B.P. Systolic Increased-non-SAE, R, Mild142006
B.P. Systolic Increased-non-SAE, R, Moderate010001
Breast Tenderness-non-SAE, NR, Mild100000
Breath Sounds Abnormal-non-SAE, NR, Mild100000
Bronchitis-non-SAE, NR, Mild110225
Bronchitis-non-SAE, NR, Moderate101045
Bursitis-non-SAE, NR, Mild100000
Candidiasis-non-SAE, NR, Mild100000
Cardiac Murmur-non-SAE, NR, Mild010001
Centrl Venous Catheterisation-non-SAE, NR, Moderat000011
Cervical Spinal Stenosis-non-SAE, NR, Moderate000011
Chest Pain-non-SAE, NR, Mild000011
Chest Pain-SAE, NR, Severe000101
Chills-non-SAE, R, Mild700000
Chills-non-SAE, R, Moderate600000
C.O.P.D.-non-SAE, NR, Moderate000101
C.O.P.D.-non-SAE, NR, Severe100000
Chronic Sinusitis-non-SAE, NR, Mild001214
Chronic Sinusitis-non-SAE, NR, Moderate000011
Confusional State-non-SAE, R, Mild100000
Conjunctival Hyperaemia-non-SAE, NR, Mild010001
Conjunctivitis Allergic-non-SAE, NR, Moderate100000
Conjunctivitis Bacterial-non-SAE, NR, Moderate001001
Conjunctivitis Infective-non-SAE, NR, Mild000011
Conjunctivitis Infective-non-SAE, NR, Moderate000011
Constipation-non-SAE, NR, Mild120013
Constipation-non-SAE, NR, Moderate000011
Contusion-non-SAE, NR, Mild010102
Contusion-non-SAE, R, Mild001001
Convulsion-non-SAE, NR, Moderate100000
Convulsion-SAE, NR, Moderate100000
Costochondritis-non-SAE, NR, Moderate010001
Costochondritis-non-SAE, NR, Severe010001
Cough-non-SAE, NR, Mild200022
Cough-non-SAE, R, Mild100000
Croup Infectious-non-SAE, NR, Mild020103
Croup Infectious-non-SAE, NR, Moderate000022
Cryptosporidiosis Infection-non-SAE, NR, Moderate001001
Cystitis-non-SAE, NR, Moderate000011
Dental Caries-non-SAE, NR, Moderate000101
Dermatitis-non-SAE, NR, Mild000011
Dermatitis-non-SAE, NR, Moderate100000
Dermatitis Contact-non-SAE, NR, Moderate111103
Device Failure-non-SAE, NR, Mild200000
Diarrhoea-non-SAE, NR, Mild120226
Diarrhoea-non-SAE, NR, Moderate221104
Diarrhoea-non-SAE, R, Mild002013
Diarrhoea Haemorrhagic-non-SAE, NR, Mild100000
Diarrhoea Infectious-non-SAE, NR, Moderate000101
Diverticulitis-non-SAE, NR, Moderate100000
Drug Eruption-non-SAE, NR, Moderate100000
Dyspepsia-non-SAE, NR, Moderate010001
Dyspnoea-non-SAE, NR, Mild001001
Dyspnoea-non-SAE, NR, Moderate000011
Dyspnoea-non-SAE, R, Mild100000
Ear Infection-non-SAE, NR, Moderate100011
Ear Pain-non-SAE, NR, Mild111024
Ear Pain-non-SAE, R, Moderate010001
Eczema-non-SAE, NR, Moderate010034
Eczema-non-SAE, NR, Severe100000
Epistaxis-non-SAE, NR, Mild000011
Epistaxis-non-SAE, NR, Moderate001012
Excoriation-non-SAE, NR, Mild000202
Exostosis-non-SAE, NR,Mild001001
Eye Infection Viral-non-SAE, NR, Moderate310214
Eye Irritation-non-SAE, R, Mild000011
Eye Oedema-non-SAE, NR, Mild010001
Fall-non-SAE, NR, Moderate000101
Fatigue-non-SAE, NR, Mild000022
Fatigue-non-SAE, NR, Moderate000011
Fatigue-non-SAE, R, Mild140206
Fatigue-non-SAE, R, Moderate000022
Flank Pain-non-SAE, NR, Mild200000
Flatulence-non-SAE, NR, Mild000011
Flatulence-non-SAE, NR, Moderate000101
Folliculitis-non-SAE, NR, Moderate100000
Fungal Infection-non-SAE, NR, Moderate001001
Furuncle-non-SAE, NR, Moderate011002
Gastric Ulcer-non-SAE, NR, Mild000101
Gastric Ulcer-non-SAE, NR, Moderate010001
Gastroenteritis-non-SAE, NR, Mild100101
Gastroenteritis-non-SAE, NR, Moderate000101
Gastroenteritis-non-SAE, R, Mild200000
Gastroenteritis Viral-non-SAE, NR, Mild220002
Gastroenteritis Viral-non-SAE, NR, Moderate010034
Goitre-non-SAE, NR, Mild100000
Gravitational Oedema-non-SAE, R, Mild010001
Haematochezia-non-SAE, NR, Mild000011
Haemoglobin Decreased-non-SAE, R, Mild000011
Haemorrhoids-non-SAE, NR, Mild000011
Head Injury-non-SAE, NR, Mild010001
Headache-non-SAE, NR, Mild8534820
Headache-non-SAE, NR, Moderate402114
Headache-non-SAE, NR, Severe001012
Headache-non-SAE, R, Mild19612817
Headache-non-SAE, R, Moderate811002
Headache-non-SAE, R, Severe310001
Heart Rate Decreased-non-SAE, R, Mild003003
Heart Rate Increased-non-SAE, NR, Mild030104
Heart Rate Increased-non-SAE, R, Mild443119
Heart Rate Increased-non-SAE, R, Moderate100000
Hiatus Hernia-non-SAE, NR, Moderate010001
Hordeolum-non-SAE, NR, Mild010001
Hyperlipidaemia-non-SAE, NR, Moderate010001
Hypoxia-non-SAE, NR, Moderate010001
Implant Site Pain-non-SAE, NR, Moderate000011
Infection-non-SAE, NR, Mild200011
Infection-non-SAE, NR, Moderate111013
Influenza-non-SAE, NR, Mild130025
Influenza-non-SAE, NR, Moderate240127
Infusion Related Reaction-non-SAE, R, Mild110001
Infusion Site Erythema-non-SAE, R, Mild030003
Infusion Site Haematoma-non-SAE, NR, Mild000112
Infusion Site Haematoma-non-SAE, R, Mild0222612
Infusion Site Haematoma-non-SAE, R, Moderate000011
Infusion Site Haemorrhage-non-SAE, R, Mild020002
Infusion Site Irritation-non-SAE, R, Mild110012
Infusion Site Oedema-non-SAE, R, Mild030003
Infusion Site Pain-non-SAE, R, Mild1922114
Infusion Site Pain-non-SAE, R, Moderate051208
Infusion Site Pruritus-non-SAE, NR, Moderate010001
Infusion Site Pruritus-non-SAE, R, Mild021104
Infusion Site Pruritus-non-SAE, R, Moderate010001
Infusion Site Rash-non-SAE, NR, Mild010001
Infusion Site Rash-non-SAE, R, Mild011013
Infusion Site Reaction-non-SAE, R, Mild000101
Infusion Site Swelling-non-SAE, R, Mild010001
Infusion Site Swelling-non-SAE, R, Moderate001001
Infusion Site Vesicles-non-SAE, R, Mild010001
Inguinal Mass-non-SAE, NR, Mild010001
Injection Site Haematoma-non-SAE, NR, Mild000101
Injection Site Haematoma-non-SAE, R, Mild010001
Injection Site Pain-non-SAE, NR, Mild000011
Insomnia-non-SAE, NR, Mild010023
Insomnia-non-SAE, NR, Moderate000101
Intermit. Explosive Disorder-non-SAE, NR, Moderate000101
Irritability-non-SAE, NR, Mild000022
Irritable Bowel Syndrome-non-SAE, NR, Moderate010113
Joint Dislocation-non-SAE, NR, Moderate000101
Joint Sprain-non-SAE, NR, Mild020002
Joint Swelling-non-SAE, NR, Mild010001
Joint Swelling-non-SAE, NR, Moderate010001
Laryngitis-non-SAE, NR, Mild001001
Laryngitis-non-SAE, NR, Moderate001001
Laryngitis Viral-non-SAE, NR, Moderate000011
Lethargy-non-SAE, NR, Mild000011
Limb Injury-non-SAE, NR, Mild100101
Lip Ulceration-non-SAE, NR, Mild000011
Livedo Reticularis-non-SAE, R, Mild100000
Lung Infection-non-SAE, NR, Moderate100000
Lung Infection-non-SAE, NR, Severe100000
Lymphadenopathy-non-SAE, NR, Mild201023
Malaise-non-SAE, NR, Moderate100101
Malaise-non-SAE, R, Moderate010001
Memory Impairment-non-SAE, NR, Moderate001001
Middle Ear Effusion-non-SAE, NR, Moderate100000
Migraine-non-SAE, NR, Mild000112
Migraine-non-SAE, NR, Moderate000011
Migraine-non-SAE, NR, Severe100000
Migraine-non-SAE, R, Moderate000011
Migraine-non-SAE, R, Severe000011
Mouth Ulceration-non-SAE, NR, Mild100000
Muscle Strain-non-SAE, NR, Mild001012
Muscular Weakness-non-SAE, NR, Moderate000101
Musculoskeletal Chest Pain-non-SAE, NR, Mild000101
Musculoskeletal Pain-non-SAE, NR, Mild000101
Musculoskeletal Pain-non-SAE, NR, Moderate001113
Myalgia-non-SAE, NR, Mild011158
Myalgia-non-SAE, NR, Moderate000101
Myopia-non-SAE, NR, Mild010001
Nasal Congestion-non-SAE, NR, Mild000022
Nasal Congestion-non-SAE, NR, Moderate001012
Nasal Disorder-non-SAE, NR, Mild010001
Nasal Mucosal Disorder-non-SAE, NR, Mild000101
Nasal Polyps-non-SAE, NR, Moderate000101
Nasopharyngitis-non-SAE, NR, Mild510146
Nasopharyngitis-non-SAE, NR, Moderate010146
Nausea-non-SAE, NR, Mild1312511
Nausea-non-SAE, NR, Moderate010214
Nausea-non-SAE, NR, Severe000011
Nausea-non-SAE, R, Mild411316
Nausea-non-SAE, R, Moderate100000
Oedema Peripheral-non-SAE, NR, Moderate010001
Oedema Peripheral-non-SAE, R, Mild000101
Oral Herpes-non-SAE, NR, Mild030014
Oropharyngeal Pain-non-SAE, NR, Mild120035
Oropharyngeal Pain-non-SAE, NR, Moderate200123
Osteomyelitis-non-SAE, NR, Moderate000011
Osteopenia-non-SAE, NR, Moderate010001
Otitis Externa-non-SAE, NR, Mild010001
Otitis Media-non-SAE, NR, Mild031004
Otitis Media-non-SAE, NR, Moderate020327
Pain-non-SAE, NR, Moderate100000
Pain In Extremity-non-SAE, NR, Mild300000
Pain In Extremity-non-SAE, NR, Moderate001102
Pain In Extremity-non-SAE, R, Moderate100101
Pain In Extremity-non-SAE, R, Severe100000
Paraesthesia-non-SAE, NR, Moderate000011
Paronychia-non-SAE, NR, Mild100000
Periorbital Oedema-non-SAE, NR, Mild000011
Pharyngitis-non-SAE, NR, Mild010012
Pharyngitis-non-SAE, NR, Moderate210203
Pharyngitis Streptococcal-non-SAE, NR, Moderate020002
Pneumonia-non-SAE, NR, Mild000101
Pneumonia-non-SAE, NR, Moderate010023
Pneumonia Bacterial-non-SAE, NR, Moderate001001
Pneumonia Streptococcal-non-SAE, NR, Mild000011
Procedural Pain-non-SAE, NR, Moderate100123
Pyrexia-non-SAE, NR, Mild13001013
Pyrexia-non-SAE, NR, Moderate100022
Pyrexia-non-SAE, R, Mild520046
Pyrexia-non-SAE, R, Moderate100011
Rales-non-SAE, NR, Moderate100000
Rash-non-SAE, NR, Mild200000
Rash-non-SAE, R, Mild010102
Rash Erythematous-non-SAE, NR, Mild010012
Rash Macular-non-SAE, NR, Mild100000
Rash Papular-non-SAE, NR, Mild000022
Rash Pruritic-non-SAE, NR, Mild000101
Respiratory Rate Increased-non-SAE, NR, Moderate000101
Respir. Tract Infect. Viral-non-SAE, NR, Mild220013
Respir. Tract Infect Viral-non-SAE, NR, Moderate110001
Rhinitis-non-SAE, NR, Moderate000011
Rhinitis Allergic-non-SAE, NR, Mild100000
Rhinorrhoea-non-SAE, NR, Mild010102
Road Traffic Accident-non-SAE, NR, Mild010001
Scleritis-non-SAE, NR, Mild100000
Scleritis-non-SAE, NR, Moderate000011
Scoliosis-non-SAE, NR, Mild010001
Sinus Congestion-non-SAE, NR, Mild100011
Sinus Congestion-non-SAE, NR, Moderate000101
Sinus Disorder-non-SAE, NR, Severe010001
Sinus Headache-non-SAE, NR, Mild100011
Sinus Headache-non-SAE, NR, Moderate210102
Sinusitis-non-SAE, NR, Mild300145
Sinusitis-non-SAE, NR, Moderate7465318
Sinusitis-SAE, NR, Moderate100000
Sinusitis Fungal-non-SAE, NR, Moderate000011
Skin Laceration-non-SAE, NR, Mild200000
Skin Lesion-non-SAE, NR, Mild100101
Skin Papilloma-non-SAE, NR, Moderate100000
Skin Warm-non-SAE, R, Mild100000
Sports Injury-non-SAE, NR, Mild010001
Streptococcal Infection-non-SAE, NR, Moderate000011
Subcutaneous Abscess-non-SAE, NR, Mild001001
Suicidal Ideation-non-SAE, NR, Mild100000
Sunburn-non-SAE, NR, Severe100000
Tendonitis-non-SAE, NR, Moderate100000
Tooth Fracture-non-SAE, NR, Moderate000011
Tooth Infection-non-SAE, NR, Moderate000101
Toothache-non-SAE, NR, Moderate010012
Tourette's Disorder-non-SAE, NR, Mild010001
Upper Respir. Tract Congestion-non-SAE, NR, Mild010001
Upper Respir. Tract Infection-non-SAE, NR, Mild4336820
Upper Respir. Tract Infect.-non-SAE, NR, Moderate210135
Urinary Tract Infection-non-SAE, NR, Moderate100011
Urticaria-non-SAE, NR, Mild000022
Urticaria-non-SAE, R, Mild000011
Vaginal Lesion-non-SAE, NR, Mild010001
Vaginitis Bacterial-non-SAE, NR, Moderate001001
Varicose Vein-non-SAE, NR, Moderate000101
Varicose Vein-non-SAE, NR, Severe000011
Vestibulitis-non-SAE, NR, Moderate000101
Viral Infection-non-SAE, NR, Mild220002
Viral Infection-non-SAE, NR, Moderate300101
Viral Skin Infection-non-SAE, NR, Mild100000
Viral Upper Respir. Tract Infect-non-SAE, NR, Mild010001
Viral Up. Respir Tract Infec-non-SAE, NR, Moderate000101
Vitamin D Deficiency-non-SAE, NR, Mild100000
Vomiting-non-SAE, NR, Mild211147
Vomiting-non-SAE, NR, Moderate001001
Vomiting-non-SAE, R, Mild800112
Vomiting-non-SAE, R, Moderate100202
Vulvovaginal Candidiasis-non-SAE, NR, Mild010001
Vulvovaginal Mycotic Infection-non-SAE, NR, Mild000101
Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate000011
Wheezing-non-SAE, NR, Mild000011
Wound-non-SAE, NR, Moderate000101
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)

Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.

Time frame:
Throughout entire study (1 year and 9 months)
Reported as:
Number · AEs per infusion
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (FSDS)
AEs per infusionStudy Part 1, IV AdministrationStudy Part 2, SC AdministrationStudy Part 3a, SC AdministrationStudy Part 3b, SC AdministrationStudy Extension, SC AdministrationTotal SC (Parts 2, 3a, 3b, Extension)
Abdominal Discomfort- non-SAE, NR, Mild0.000.000.000.000.040.04
Abdominal Distension-non-SAE, NR, Mild0.000.000.000.000.290.29
Abdominal Distension-non-SAE, NR, Moderate0.000.000.000.170.080.13
Abdominal Distension-non-SAE, R, Mild0.000.080.000.080.000.08
Abdominal Distension-non-SAE, R, Moderate0.000.080.000.000.000.08
Abdominal Pain-non-SAE, NR, Mild0.250.000.170.000.050.11
Abdominal Pain-non-SAE, NR, Moderate0.000.000.000.000.050.05
Abdominal Pain Upper-non-SAE, NR, Mild0.500.000.000.000.030.03
Abdominal Pain Upper-non-SAE, NR, Moderate0.000.000.000.000.080.08
Abdominal Pain Upper-non-SAE, R, Mild0.000.100.170.000.000.13
Abdominal Tenderness-non-SAE, NR, Mild0.000.000.000.080.000.08
Acne-non-SAE, NR, Mild0.000.080.000.000.000.08
Acne-non-SAE, NR, Moderate0.000.000.000.080.000.08
Acute Sinusitis-non-SAE, NR, Moderate0.000.080.000.000.000.08
Addison's Disease-non-SAE, NR, Mild0.000.080.000.000.000.08
Addison's Disease-non-SAE, NR, Moderate0.200.000.000.000.000.00
Alopecia-non-SAE, NR, Mild0.250.000.000.000.000.00
Ammonia Increased-non-SAE, NR, Mild0.000.080.000.000.000.08
Animal Bite-non-SAE, NR, Moderate0.200.000.000.000.000.00
Anorexia-non-SAE, NR, Moderate0.000.000.170.000.000.17
Anxiety-non-SAE, NR, Mild0.000.000.000.000.030.03
Aphthous Stomatitis-non-SAE, NR, Mild0.000.080.170.000.140.14
Arthralgia-non-SAE, NR, Moderate0.000.100.170.170.040.11
Arthralgia-non-SAE, NR, Severe0.000.000.000.000.040.04
Arthralgia-non-SAE, R, Mild0.250.000.170.000.000.17
Arthralgia-non-SAE, R, Moderate0.250.000.000.000.000.00
Arthritis-non-SAE, NR, Moderate0.000.000.170.000.000.17
Arthropod Bite-non-SAE, NR, Mild0.000.080.000.000.030.06
Asthenia-non-SAE, NR, Mild0.000.000.000.080.000.08
Asthenia-non-SAE, NR, Moderate0.000.000.170.000.000.17
Asthma-non-SAE, NR, Mild0.000.000.000.000.040.04
Asthma-non-SAE, NR, Moderate0.250.000.170.080.030.04
Asthma-non-SAE, NR, Severe0.000.000.000.080.000.08
Asthma-non-SAE, R, Mild0.000.080.000.000.000.08
Asthma Exercise Induced-non-SAE, NR, Moderate0.000.080.000.000.000.08
ADHD-non-SAE, NR, Mild0.000.070.000.000.000.07
Back Pain-non-SAE, NR, Mild0.250.000.000.090.000.09
Back Pain-non-SAE, NR, Moderate0.250.000.000.170.000.17
Back Pain-non-SAE, R, Moderate0.200.000.000.000.000.00
Biliary Tract Infection Bacterial-SAE, NR, Moderat0.000.070.000.000.000.07
Blepharitis-non-SAE,NR, Mild0.000.000.170.000.000.17
Blepharitis-non-SAE,NR, Moderate0.250.000.000.000.000.00
B.P. Diastolic Decreased-non-SAE, R, Mild0.000.000.330.000.000.33
Blood Pressure Increased-non-SAE, NR, Mild0.000.000.000.170.000.17
Blood Pressure Increased-non-SAE, R, Mild0.000.000.000.080.000.08
B.P. Systolic Increased-non-SAE, NR, Mild0.000.080.170.000.000.12
B.P. Systolic Increased-non-SAE, NR, Moderate0.000.000.000.080.000.08
B.P. Systolic Increased-non-SAE, R, Mild0.250.160.170.000.000.17
B.P. Systolic Increased-non-SAE, R, Moderate0.000.080.000.000.000.08
Breast Tenderness-non-SAE, NR, Mild0.250.000.000.000.000.00
Breath Sounds Abnormal-non-SAE, NR, Mild0.200.000.000.000.000.00
Bronchitis-non-SAE, NR, Mild0.250.080.000.170.060.08
Bronchitis-non-SAE, NR, Moderate0.250.000.170.000.070.08
Bursitis-non-SAE, NR, Mild0.250.000.000.000.000.00
Candidiasis-non-SAE, NR, Mild0.250.000.000.000.000.00
Cardiac Murmur-non-SAE, NR, Mild0.000.080.000.000.000.08
Centrl Venous Catheterisation-non-SAE, NR, Moderat0.000.000.000.000.030.03
Cervical Spinal Stenosis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Chest Pain-non-SAE, NR, Mild0.000.000.000.000.050.05
Chest Pain-SAE, NR, Severe0.000.000.000.080.000.08
Chills-non-SAE, R, Mild0.750.000.000.000.000.00
Chills-non-SAE, R, Moderate0.750.000.000.000.000.00
C.O.P.D.-non-SAE, NR, Moderate0.000.000.000.080.000.08
C.O.P.D.-non-SAE, NR, Severe0.250.000.000.000.000.00
Chronic Sinusitis-non-SAE, NR, Mild0.000.000.170.080.030.08
Chronic Sinusitis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Confusional State-non-SAE, R, Mild0.250.000.000.000.000.00
Conjunctival Hyperaemia-non-SAE, NR, Mild0.000.080.000.000.000.08
Conjunctivitis Allergic-non-SAE, NR, Moderate0.200.000.000.000.000.00
Conjunctivitis Bacterial-non-SAE, NR, Moderate0.000.000.170.000.000.17
Conjunctivitis Infective-non-SAE, NR, Mild0.000.000.000.000.040.04
Conjunctivitis Infective-non-SAE, NR, Moderate0.000.000.000.000.030.03
Constipation-non-SAE, NR, Mild0.250.080.000.000.030.07
Constipation-non-SAE, NR, Moderate0.000.000.000.000.030.03
Contusion-non-SAE, NR, Mild0.000.080.000.080.000.08
Contusion-non-SAE, R, Mild0.000.000.170.000.000.17
Convulsion-non-SAE, NR, Moderate0.250.000.000.000.000.00
Convulsion-SAE, NR, Moderate0.250.000.000.000.000.00
Costochondritis-non-SAE, NR, Moderate0.000.080.000.000.000.08
Costochondritis-non-SAE, NR, Severe0.000.080.000.000.000.08
Cough-non-SAE, NR, Mild0.500.000.000.000.050.05
Cough-non-SAE, R, Mild0.250.000.000.000.000.00
Croup Infectious-non-SAE, NR, Mild0.000.080.000.080.000.08
Croup Infectious-non-SAE, NR, Moderate0.000.000.000.000.110.11
Cryptosporidiosis Infection-non-SAE, NR, Moderate0.000.000.170.000.000.17
Cystitis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Dental Caries-non-SAE, NR, Moderate0.000.000.000.080.000.08
Dermatitis-non-SAE, NR, Mild0.000.000.000.000.030.03
Dermatitis-non-SAE, NR, Moderate0.250.000.000.000.000.00
Dermatitis Contact-non-SAE, NR, Moderate0.250.080.170.080.000.08
Device Failure-non-SAE, NR, Mild0.230.000.000.000.000.00
Diarrhoea-non-SAE, NR, Mild0.250.070.000.170.050.06
Diarrhoea-non-SAE, NR, Moderate0.250.170.170.080.000.17
Diarrhoea-non-SAE, R, Mild0.000.000.330.000.050.19
Diarrhoea Haemorrhagic-non-SAE, NR,Mild0.250.000.000.000.000.00
Diarrhoea Infectious-non-SAE, NR, Moderate0.000.000.000.080.000.08
Diverticulitis-non-SAE, NR, Moderate0.250.000.000.000.000.00
Drug Eruption-non-SAE, NR, Moderate0.250.000.000.000.000.00
Dyspepsia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Dyspnoea-non-SAE, NR, Mild0.000.000.170.000.000.17
Dyspnoea-non-SAE, NR, Moderate0.000.000.000.000.050.05
Dyspnoea-non-SAE, R, Mild0.250.000.000.000.000.00
Ear Infection-non-SAE, NR, Moderate0.250.000.000.000.050.05
Ear Pain-non-SAE, NR, Mild0.250.060.170.000.040.05
Ear Pain-non-SAE, R, Moderate0.000.060.000.000.000.06
Eczema-non-SAE, NR, Moderate0.000.080.000.000.040.06
Eczema-non-SAE, NR, Severe0.200.000.000.000.000.00
Epistaxis-non-SAE, NR, Mild0.000.000.000.000.030.03
Epistaxis-non-SAE, NR, Moderate0.000.000.140.000.070.10
Excoriation-non-SAE, NR, Mild0.000.000.000.170.000.17
Exostosis-non-SAE, NR,Mild0.000.000.170.000.000.17
Eye Infection Viral-non-SAE, NR, Moderate0.380.100.000.080.040.08
Eye Irritation-non-SAE, R, Mild0.000.000.000.000.040.04
Eye Oedema-non-SAE, NR, Mild0.000.080.000.000.000.08
Fall-non-SAE, NR, Moderate0.000.000.000.080.000.08
Fatigue-non-SAE, NR, Mild0.000.000.000.000.110.11
Fatigue-non-SAE, NR, Moderate0.000.000.000.000.030.03
Fatigue-non-SAE, R, Mild0.250.160.000.170.000.21
Fatigue-non-SAE, R, Moderate0.000.000.000.000.070.07
Flank Pain-non-SAE, NR, Mild0.500.000.000.000.000.00
Flatulence-non-SAE, NR, Mild0.000.000.000.000.040.04
Flatulence-non-SAE, NR, Moderate0.000.000.000.080.000.08
Folliculitis-non-SAE, NR, Moderate0.250.000.000.000.000.00
Fungal Infection-non-SAE, NR, Moderate0.000.000.170.000.000.17
Furuncle-non-SAE, NR, Moderate0.000.080.170.000.000.12
Gastric Ulcer-non-SAE, NR, Mild0.000.000.000.090.000.09
Gastric Ulcer-non-SAE, NR, Moderate0.000.080.000.000.000.08
Gastroenteritis-non-SAE, NR, Mild0.250.000.000.080.000.08
Gastroenteritis-non-SAE, NR, Moderate0.000.000.000.080.000.08
Gastroenteritis-non-SAE, R, Mild0.250.000.000.000.000.00
Gastroenteritis Viral-non-SAE, NR, Mild0.230.060.000.000.000.06
Gastroenteritis Viral-non-SAE, NR, Moderate0.000.080.000.000.050.07
Goitre-non-SAE, NR, Mild0.250.000.000.000.000.00
Gravitational Oedema-non-SAE, R, Mild0.000.080.000.000.000.08
Haematochezia-non-SAE, NR, Mild0.000.000.000.000.030.03
Haemoglobin Decreased-non-SAE, R, Mild0.000.000.000.000.030.03
Haemorrhoids-non-SAE, NR, Mild0.000.000.000.000.040.04
Head Injury-non-SAE, NR, Mild0.000.080.000.000.000.08
Headache-non-SAE, NR, Mild0.230.170.170.080.040.08
Headache-non-SAE, NR, Moderate0.250.000.170.080.030.13
Headache-non-SAE, NR, Severe0.000.000.170.000.070.12
Headache-non-SAE, R, Mild1.100.200.170.170.110.14
Headache-non-SAE, R, Moderate0.630.070.170.000.000.24
Headache-non-SAE, R, Severe0.380.070.000.000.000.07
Heart Rate Decreased-non-SAE, R, Mild0.000.000.500.000.000.50
Heart Rate Increased-non-SAE, NR, Mild0.000.250.000.080.000.17
Heart Rate Increased-non-SAE, R, Mild0.250.080.250.080.030.08
Heart Rate Increased-non-SAE, R, Moderate0.250.000.000.000.000.00
Hiatus Hernia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Hordeolum-non-SAE, NR, Mild0.000.080.000.000.000.08
Hyperlipidaemia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Hypoxia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Implant Site Pain-non-SAE, NR, Moderate0.000.000.000.000.040.04
Infection-non-SAE, NR, Mild0.500.000.000.000.050.05
Infection-non-SAE, NR, Moderate0.200.080.170.000.040.08
Influenza-non-SAE, NR, Mild0.250.080.000.000.030.08
Influenza-non-SAE, NR, Moderate0.230.070.000.080.040.07
Infusion Related Reaction-non-SAE, R, Mild0.250.080.000.000.000.08
Infusion Site Erythema-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Haematoma-non-SAE, NR, Mild0.000.000.000.080.030.06
Infusion Site Haematoma-non-SAE, R, Mild0.000.070.170.170.040.07
Infusion Site Haematoma-non-SAE, R, Moderate0.000.000.000.000.040.04
Infusion Site Haemorrhage-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Irritation-non-SAE, R, Mild0.250.100.000.000.050.07
Infusion Site Oedema-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Pain-non-SAE, R, Mild0.200.140.150.080.040.16
Infusion Site Pain-non-SAE, R, Moderate0.000.070.170.160.000.16
Infusion Site Pruritus-non-SAE, NR, Moderate0.000.070.000.000.000.07
Infusion Site Pruritus-non-SAE, R, Mild0.000.150.170.080.000.16
Infusion Site Pruritus-non-SAE, R, Moderate0.000.070.000.000.000.07
Infusion Site Rash-non-SAE, NR, Mild0.000.060.000.000.000.06
Infusion Site Rash-non-SAE, R, Mild0.000.080.170.000.030.08
Infusion Site Reaction-non-SAE, R, Mild0.000.000.000.090.000.09
Infusion Site Swelling-non-SAE, R, Mild0.000.000.170.000.000.17
Infusion Site Swelling-non-SAE, R, Moderate0.000.080.000.000.000.08
Infusion Site Vesicles-non-SAE, R, Mild0.000.080.000.000.000.08
Inguinal Mass-non-SAE, NR, Mild0.000.080.000.000.000.08
Injection Site Haematoma-non-SAE, NR, Mild0.000.000.000.080.000.08
Injection Site Haematoma-non-SAE, R, Mild0.000.080.000.000.000.08
Injection Site Pain-non-SAE, NR, Mild0.000.000.000.000.040.04
Insomnia-non-SAE, NR, Mild0.000.070.000.000.030.03
Insomnia-non-SAE, NR, Moderate0.000.000.000.080.000.08
Intermit. Explosive Disorder-non-SAE, NR, Moderate0.000.000.000.080.000.08
Irritability-non-SAE, NR, Mild0.000.000.000.000.130.13
Irritable Bowel Syndrome-non-SAE, NR, Moderate0.000.060.000.080.040.06
Joint Dislocation-non-SAE, NR, Moderate0.000.000.000.080.000.08
Joint Sprain-non-SAE, NR, Mild0.000.170.000.000.000.17
Joint Swelling-non-SAE, NR, Mild0.000.080.000.000.000.08
Joint Swelling-non-SAE, NR, Moderate0.000.080.000.000.000.08
Laryngitis-non-SAE, NR, Mild0.000.000.170.000.000.17
Laryngitis-non-SAE, NR, Moderate0.000.000.170.000.000.17
Laryngitis Viral-non-SAE, NR, Moderate0.000.000.000.000.030.03
Lethargy-non-SAE, NR, Mild0.000.000.000.000.070.07
Limb Injury-non-SAE, NR, Mild0.250.000.000.080.000.08
Lip Ulceration-non-SAE, NR, Mild0.000.000.000.000.030.03
Livedo Reticularis-non-SAE, R, Mild0.250.000.000.000.000.00
Lung Infection-non-SAE, NR, Moderate0.250.000.000.000.000.00
Lung Infection-non-SAE, NR, Severe0.250.000.000.000.000.00
Lymphadenopathy-non-SAE, NR, Mild0.250.000.170.000.040.05
Malaise-non-SAE, NR, Moderate0.250.000.000.080.000.08
Malaise-non-SAE, R, Moderate0.000.100.000.000.000.10
Memory Impairment-non-SAE, NR, Moderate0.000.000.170.000.000.17
Middle Ear Effusion-non-SAE, NR, Moderate0.250.000.000.000.000.00
Migraine-non-SAE, NR, Mild0.000.000.000.080.030.06
Migraine-non-SAE, NR, Moderate0.000.000.000.000.040.04
Migraine-non-SAE, NR, Severe0.200.000.000.000.000.00
Migraine-non-SAE, R, Moderate0.000.000.000.000.040.04
Migraine-non-SAE, R, Severe0.000.000.000.000.070.07
Mouth Ulceration-non-SAE, NR, Mild0.250.000.000.000.000.00
Muscle Strain-non-SAE, NR, Mild0.000.000.170.000.030.10
Muscular Weakness-non-SAE, NR, Moderate0.000.000.000.080.000.08
Musculoskeletal Chest Pain-non-SAE, NR, Mild0.000.000.000.090.000.09
Musculoskeletal Pain-non-SAE, NR, Mild0.000.000.000.080.000.08
Musculoskeletal Pain-non-SAE, NR, Moderate0.000.000.170.070.040.07
Myalgia-non-SAE, NR, Mild0.000.080.170.080.090.09
Myalgia-non-SAE, NR, Moderate0.000.000.000.080.000.08
Myopia-non-SAE, NR, Mild0.000.100.000.000.000.10
Nasal Congestion-non-SAE, NR, Mild0.000.000.000.000.060.06
Nasal Congestion-non-SAE, NR, Moderate0.000.000.170.000.040.10
Nasal Disorder-non-SAE, NR, Mild0.000.070.000.000.000.07
Nasal Mucosal Disorder-non-SAE, NR, Mild0.000.000.000.080.000.08
Nasal Polyps-non-SAE, NR, Moderate0.000.000.000.080.000.08
Nasopharyngitis-non-SAE, NR, Mild0.250.080.000.080.040.04
Nasopharyngitis-non-SAE, NR, Moderate0.000.080.000.070.070.07
Nausea-non-SAE, NR, Mild0.250.080.170.080.120.08
Nausea-non-SAE, NR, Moderate0.000.070.000.170.030.07
Nausea-non-SAE, NR, Severe0.000.000.000.000.070.07
Nausea-non-SAE, R, Mild0.750.080.170.270.040.13
Nausea-non-SAE, R, Moderate0.250.000.000.000.000.00
Oedema Peripheral-non-SAE, NR, Moderate0.000.080.000.000.000.08
Oedema Peripheral-non-SAE, R, Mild0.000.000.000.080.000.08
Oral Herpes-non-SAE, NR, Mild0.000.080.000.000.030.07
Oropharyngeal Pain-non-SAE, NR, Mild0.200.080.000.000.070.07
Oropharyngeal Pain-non-SAE, NR, Moderate0.230.000.000.080.050.07
Osteomyelitis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Osteopenia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Otitis Externa-non-SAE, NR, Mild0.000.080.000.000.000.08
Otitis Media-non-SAE, NR, Mild0.000.130.170.000.000.17
Otitis Media-non-SAE, NR, Moderate0.000.170.000.130.110.14
Pain-non-SAE, NR, Moderate0.250.000.000.000.000.00
Pain In Extremity-non-SAE, NR, Mild0.380.000.000.000.000.00
Pain In Extremity-non-SAE, NR, Moderate0.000.000.170.080.000.13
Pain In Extremity-non-SAE, R, Moderate0.250.000.000.080.000.08
Pain In Extremity-non-SAE, R, Severe0.250.000.000.000.000.00
Paraesthesia-non-SAE, NR, Moderate0.000.000.000.000.030.03
Paronychia-non-SAE, NR, Mild0.250.000.000.000.000.00
Periorbital Oedema-non-SAE, NR, Mild0.000.000.000.000.070.07
Pharyngitis-non-SAE, NR, Mild0.000.080.000.000.050.07
Pharyngitis-non-SAE, NR, Moderate0.500.080.000.080.000.08
Pharyngitis Streptococcal-non-SAE, NR, Moderate0.000.080.000.000.000.08
Pneumonia-non-SAE, NR, Mild0.000.000.000.080.000.08
Pneumonia-non-SAE, NR, Moderate0.000.080.000.000.040.06
Pneumonia Bacterial-non-SAE, NR, Moderate0.000.000.170.000.000.17
Pneumonia Streptococcal-non-SAE, NR, Mild0.000.000.000.000.070.07
Procedural Pain-non-SAE, NR, Moderate0.250.000.000.080.040.04
Pyrexia-non-SAE, NR, Mild0.250.070.000.000.070.07
Pyrexia-non-SAE, NR, Moderate0.250.000.000.000.030.03
Pyrexia-non-SAE, R, Mild0.630.170.000.000.070.07
Pyrexia-non-SAE, R, Moderate0.250.000.000.000.030.03
Rales-non-SAE, NR, Moderate0.250.000.000.000.000.00
Rash-non-SAE, NR, Mild0.250.000.000.000.000.00
Rash-non-SAE, R, Mild0.000.080.000.080.000.08
Rash Erythematous-non-SAE, NR, Mild0.000.080.000.000.050.07
Rash Macular-non-SAE, NR, Mild0.250.000.000.000.000.00
Rash Papular-non-SAE, NR, Mild0.000.000.000.000.030.03
Rash Pruritic-non-SAE, NR, Mild0.000.000.000.080.000.08
Respiratory Rate Increased-non-SAE, NR, Moderate0.000.000.000.080.000.08
Respir. Tract Infect. Viral-non-SAE, NR, Mild0.250.170.000.000.030.10
Respir. Tract Infect Viral-non-SAE, NR, Moderate0.250.080.000.000.000.08
Rhinitis-non-SAE, NR, Moderate0.000.000.000.000.090.09
Rhinitis Allergic-non-SAE, NR, Mild0.250.000.000.000.000.00
Rhinorrhoea-non-SAE, NR, Mild0.000.080.000.080.000.08
Road Traffic Accident-non-SAE, NR, Mild0.000.070.000.000.000.07
Scleritis-non-SAE, NR, Mild0.200.000.000.000.000.00
Scleritis-non-SAE, NR, Moderate0.000.000.000.000.040.04
Scoliosis-non-SAE, NR, Mild0.000.080.000.000.000.08
Sinus Congestion-non-SAE, NR, Mild0.200.000.000.000.040.04
Sinus Congestion-non-SAE, NR, Moderate0.000.000.000.080.000.08
Sinus Disorder-non-SAE, NR, Severe0.000.060.000.000.000.06
Sinus Headache-non-SAE, NR, Mild0.200.000.000.000.040.04
Sinus Headache-non-SAE, NR, Moderate0.500.070.000.080.000.08
Sinusitis-non-SAE, NR, Mild0.460.000.000.080.040.04
Sinusitis-non-SAE, NR, Moderate0.250.070.170.080.040.08
Sinusitis-SAE, NR, Moderate0.200.000.000.000.000.00
Sinusitis Fungal-non-SAE, NR, Moderate0.000.000.000.000.070.07
Skin Laceration-non-SAE, NR, Mild0.500.000.000.000.000.00
Skin Lesion-non-SAE, NR, Mild0.250.000.000.080.000.08
Skin Papilloma-non-SAE, NR, Moderate0.200.000.000.000.000.00
Skin Warm-non-SAE, R, Mild0.250.000.000.000.000.00
Sports Injury-non-SAE, NR, Mild0.000.080.000.000.000.08
Streptococcal Infection-non-SAE, NR, Moderate0.000.000.000.000.030.03
Subcutaneous Abscess-non-SAE, NR, Mild0.000.000.170.000.000.17
Suicidal Ideation-non-SAE, NR, Mild0.200.000.000.000.000.00
Sunburn-non-SAE, NR, Severe0.250.000.000.000.000.00
Tendonitis-non-SAE, NR, Moderate0.250.000.000.000.000.00
Tooth Fracture-non-SAE, NR, Moderate0.000.000.000.000.040.04
Tooth Infection-non-SAE, NR, Moderate0.000.000.000.080.000.08
Toothache-non-SAE, NR, Moderate0.000.070.000.000.030.05
Tourette's Disorder-non-SAE, NR, Mild0.000.070.000.000.000.07
Upper Respir. Tract Congestion-non-SAE, NR, Mild0.000.080.000.000.000.08
Upper Respir. Tract Infection-non-SAE, NR, Mild0.250.080.170.080.050.08
Upper Respir. Tract Infect.-non-SAE, NR, Moderate0.250.080.000.080.050.07
Urinary Tract Infection-non-SAE, NR, Moderate0.250.000.000.000.040.04
Urticaria-non-SAE, NR, Mild0.000.000.000.000.050.05
Urticaria-non-SAE, R, Mild0.000.000.000.000.070.07
Vaginal Lesion-non-SAE, NR, Mild0.000.080.000.000.000.08
Vaginitis Bacterial-non-SAE, NR, Moderate0.000.000.170.000.000.17
Varicose Vein-non-SAE, NR, Moderate0.000.000.000.080.000.08
Varicose Vein-non-SAE, NR, Severe0.000.000.000.000.040.04
Vestibulitis-non-SAE, NR, Moderate0.000.000.000.080.000.08
Viral Infection-non-SAE, NR, Mild0.250.080.000.000.000.08
Viral Infection-non-SAE, NR, Moderate0.380.000.000.080.000.08
Viral Skin Infection-non-SAE, NR, Mild0.250.000.000.000.000.00
Viral Upper Respir. Tract Infect-non-SAE, NR, Mild0.000.080.000.000.000.08
Viral Up. Respir Tract Infec-non-SAE, NR, Moderate0.000.000.000.080.000.08
Vitamin D Deficiency-non-SAE, NR, Mild0.250.000.000.000.000.00
Vomiting-non-SAE, NR, Mild0.250.070.170.080.040.07
Vomiting-non-SAE, NR, Moderate0.000.000.170.000.000.17
Vomiting-non-SAE, R, Mild0.750.000.000.090.050.07
Vomiting-non-SAE, R, Moderate0.250.000.000.180.000.18
Vulvovaginal Candidiasis-non-SAE, NR, Mild0.000.080.000.000.000.08
Vulvovaginal Mycotic Infection-non-SAE, NR, Mild0.000.000.000.080.000.08
Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate0.000.000.000.000.030.03
Wheezing-non-SAE, NR, Mild0.000.000.000.000.090.09
Wound-non-SAE, NR, Moderate0.000.000.000.080.000.08
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC -All Ages)

Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR

Time frame:
Throughout entire study (1 year and 9 months)
Reported as:
Number · Adverse events
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC -All Ages)
Adverse eventsStudy Part 1, IV AdministrationStudy Part 2, SC AdministrationStudy Part 3a, SC AdministrationStudy Part 3b, SC AdministrationStudy Extension, SC AdministrationTotal SC (Study Parts 2, 3a, 3b, Extension)
Abdominal Discomfort- non-SAE, NR, Mild000022
Abdominal Pain-non-SAE, NR, Mild000011
Abdominal Pain-non-SAE, NR, Moderate000011
Abdominal Pain Upper-non-SAE, NR, Mild200022
Abdominal Pain Upper-non-SAE, R, Mild030003
Acne-non-SAE, NR, Mild010001
Acute Sinusitis-non-SAE, NR, Moderate010001
Alopecia-non-SAE, NR, Mild100000
Ammonia Increased-non-SAE, NR, Mild010001
Animal Bite-non-SAE, NR, Moderate100000
Anorexia-non-SAE, NR, Moderate001001
Anxiety-non-SAE, NR, Mild000011
Aphthous Stomatitis-non-SAE, NR, Mild011024
Arthralgia-non-SAE, NR, Moderate020002
Arthralgia-non-SAE, R, Mild101001
Arthralgia-non-SAE, R, Moderate100000
Arthritis-non-SAE, NR, Moderate001001
Arthropod Bite-non-SAE, NR, Mild010012
Asthenia-non-SAE, NR, Mild000101
Asthma-non-SAE, NR, Mild000022
Asthma-non-SAE, NR, Moderate301135
Asthma-non-SAE, NR, Severe000101
Asthma-non-SAE, R, Mild010001
Asthma Exercise Induced-non-SAE, NR, Moderate010001
ADHD-non-SAE, NR, Mild010001
Back Pain-non-SAE, NR, Mild100101
Back Pain-non-SAE, NR, Moderate100000
Back Pain-non-SAE, R, Moderate100000
Biliary Tract Infection Bacterial-SAE, NR, Moderat010001
Blepharitis-non-SAE,NR, Moderate100000
B.P. Diastolic Decreased-non-SAE, R, Mild002002
Blood Pressure Increased-non-SAE, NR, Mild000202
Blood Pressure Increased-non-SAE, R, Mild000101
B.P. Systolic Increased-non-SAE, NR, Mild011002
B.P. Systolic Increased-non-SAE, NR, Moderate000101
B.P. Systolic Increased-non-SAE, R, Mild142006
B.P. Systolic Increased-non-SAE, R, Moderate010001
Breast Tenderness-non-SAE, NR, Mild100000
Bronchitis-non-SAE, NR, Mild110225
Bronchitis-non-SAE, NR, Moderate101023
Bursitis-non-SAE, NR, Mild100000
Candidiasis-non-SAE, NR, Mild100000
Cardiac Murmur-non-SAE, NR, Mild010001
Centrl Venous Catheterisation-non-SAE, NR, Moderat000011
Cervical Spinal Stenosis-non-SAE, NR, Moderate000011
Chest Pain-non-SAE, NR, Mild000011
Chest Pain-SAE, NR, Severe000101
Chills-non-SAE, R, Mild700000
Chills-non-SAE, R, Moderate600000
C.O.P.D.-non-SAE, NR, Moderate000101
C.O.P.D.-non-SAE, NR, Severe100000
Chronic Sinusitis-non-SAE, NR, Mild001113
Confusional State-non-SAE, R, Mild100000
Conjunctival Hyperaemia-non-SAE, NR, Mild010001
Conjunctivitis Allergic-non-SAE, NR, Moderate100000
Conjunctivitis Infective-non-SAE, NR, Mild000011
Constipation-non-SAE, NR, Mild120013
Constipation-non-SAE, NR, Moderate000011
Contusion-non-SAE, NR, Mild010102
Contusion-non-SAE, R, Mild001001
Convulsion-non-SAE, NR, Moderate100000
Convulsion-SAE, NR, Moderate100000
Cough-non-SAE, NR, Mild000022
Cough-non-SAE, R, Mild100000
Croup Infectious-non-SAE, NR, Mild020103
Croup Infectious-non-SAE, NR, Moderate000022
Cryptosporidiosis Infection-non-SAE, NR, Moderate001001
Dental Caries-non-SAE, NR, Moderate000101
Dermatitis-non-SAE, NR, Mild000011
Dermatitis Contact-non-SAE, NR, Moderate001001
Device Failure-non-SAE, NR, Mild200000
Diarrhoea-non-SAE, NR, Mild110012
Diarrhoea-non-SAE, NR, Moderate121003
Diarrhoea-non-SAE, R, Mild100011
Diarrhoea Haemorrhagic-non-SAE, NR,Mild100000
Diarrhoea Infectious-non-SAE, NR, Moderate000101
Diverticulitis-non-SAE, NR, Moderate100000
Drug Eruption-non-SAE, NR, Moderate100000
Dyspnoea-non-SAE, NR, Moderate000011
Dyspnoea-non-SAE, R, Mild100000
Ear Infection-non-SAE, NR, Moderate100011
Ear Pain-non-SAE, NR, Mild011013
Ear Pain-non-SAE, R, Moderate010001
Eczema-non-SAE, NR, Moderate010034
Eczema-non-SAE, NR, Severe100000
Epistaxis-non-SAE, NR, Mild000011
Epistaxis-non-SAE, NR, Moderate001012
Excoriation-non-SAE, NR, Mild000202
Eye Infection Viral-non-SAE, NR, Moderate310113
Fall-non-SAE, NR, Moderate000101
Fatigue-non-SAE, NR, Mild000022
Fatigue-non-SAE, NR, Moderate000011
Fatigue-non-SAE, R, Mild130205
Fatigue-non-SAE, R, Moderate000022
Flank Pain-non-SAE, NR, Mild200000
Fungal Infection-non-SAE, NR, Moderate001001
Furuncle-non-SAE, NR, Moderate011002
Gastric Ulcer-non-SAE, NR, Mild000101
Gastric Ulcer-non-SAE, NR, Moderate010001
Gastroenteritis-non-SAE, NR, Mild100101
Gastroenteritis-non-SAE, NR, Moderate000101
Gastroenteritis-non-SAE, R, Mild020000
Gastroenteritis Viral-non-SAE, NR, Mild120002
Gastroenteritis Viral-non-SAE, NR, Moderate010034
Goitre-non-SAE, NR, Mild100000
Gravitational Oedema-non-SAE, R, Mild010001
Haematochezia-non-SAE, NR, Mild000011
Haemoglobin Decreased-non-SAE, R, Mild000011
Haemorrhoids-non-SAE, NR, Mild000011
Head Injury-non-SAE, NR, Mild010001
Headache-non-SAE, NR, Mild7323816
Headache-non-SAE, NR, Moderate402114
Headache-non-SAE, NR, Severe001012
Headache-non-SAE, R, Mild19412815
Headache-non-SAE, R, Moderate811002
Headache-non-SAE, R, Severe310001
Heart Rate Decreased-non-SAE, R, Mild003003
Heart Rate Increased-non-SAE, NR, Mild030104
Heart Rate Increased-non-SAE, R, Mild443119
Heart Rate Increased-non-SAE, R, Moderate100000
Hiatus Hernia-non-SAE, NR, Moderate010001
Hordeolum-non-SAE, NR, Mild010001
Hyperlipidaemia-non-SAE, NR, Moderate010001
Hypoxia-non-SAE, NR, Moderate010001
Implant Site Pain-non-SAE, NR, Moderate000011
Infection-non-SAE, NR, Mild200011
Infection-non-SAE, NR, Moderate110001
Influenza-non-SAE, NR, Mild130025
Influenza-non-SAE, NR, Moderate140026
Infusion Related Reaction-non-SAE, R, Mild110001
Infusion Site Erythema-non-SAE, R, Mild030003
Infusion Site Haematoma-non-SAE, NR, Mild000112
Infusion Site Haematoma-non-SAE, R, Mild0222511
Infusion Site Haematoma-non-SAE, R, Moderate000011
Infusion Site Haemorrhage-non-SAE, R, Mild010001
Infusion Site Irritation-non-SAE, R, Mild110001
Infusion Site Oedema-non-SAE, R, Mild020002
Infusion Site Pain-non-SAE, R, Mild1822113
Infusion Site Pain-non-SAE, R, Moderate051208
Infusion Site Pruritus-non-SAE, NR, Moderate010001
Infusion Site Pruritus-non-SAE, R, Mild011103
Infusion Site Pruritus-non-SAE, R, Moderate010001
Infusion Site Rash-non-SAE, NR, Mild010001
Infusion Site Rash-non-SAE, R, Mild011013
Infusion Site Reaction-non-SAE, R, Mild000101
Infusion Site Swelling-non-SAE, R, Mild010001
Infusion Site Swelling-non-SAE, R, Moderate001001
Infusion Site Vesicles-non-SAE, R, Mild010001
Inguinal Mass-non-SAE, NR, Mild010001
Injection Site Haematoma-non-SAE, NR, Mild000101
Insomnia-non-SAE, NR, Mild010023
Insomnia-non-SAE, NR, Moderate000101
Intermit. Explosive Disorder-non-SAE, NR, Moderate000101
Irritability-non-SAE, NR, Mild000022
Irritable Bowel Syndrome-non-SAE, NR, Moderate010113
Joint Dislocation-non-SAE, NR, Moderate000101
Laryngitis-non-SAE, NR, Mild001001
Laryngitis-non-SAE, NR, Moderate001001
Lethargy-non-SAE, NR, Mild000011
Limb Injury-non-SAE, NR, Mild000101
Lip Ulceration-non-SAE, NR, Mild000011
Livedo Reticularis-non-SAE, R, Mild100000
Lung Infection-non-SAE, NR, Moderate100000
Lung Infection-non-SAE, NR, Severe100000
Lymphadenopathy-non-SAE, NR, Mild100022
Malaise-non-SAE, NR, Moderate100101
Malaise-non-SAE, R, Moderate010001
Middle Ear Effusion-non-SAE, NR, Moderate100000
Migraine-non-SAE, NR, Mild000112
Migraine-non-SAE, NR, Severe100000
Migraine-non-SAE, R, Severe000011
Mouth Ulceration-non-SAE, NR, Mild100000
Muscular Weakness-non-SAE, NR, Moderate000101
Musculoskeletal Chest Pain-non-SAE, NR, Mild000101
Musculoskeletal Pain-non-SAE, NR, Mild000101
Musculoskeletal Pain-non-SAE, NR, Moderate001113
Myalgia-non-SAE, NR, Mild011158
Myalgia-non-SAE, NR, Moderate000101
Myopia-non-SAE, NR, Mild010001
Nasal Congestion-non-SAE, NR, Mild000011
Nasal Congestion-non-SAE, NR, Moderate001001
Nasal Disorder-non-SAE, NR, Mild010001
Nasal Mucosal Disorder-non-SAE, NR, Mild000101
Nasal Polyps-non-SAE, NR, Moderate000101
Nasopharyngitis-non-SAE, NR, Mild300123
Nasopharyngitis-non-SAE, NR, Moderate010124
Nausea-non-SAE, NR, Mild120114
Nausea-non-SAE, NR, Moderate010214
Nausea-non-SAE, NR, Severe000011
Nausea-non-SAE, R, Mild400303
Oedema Peripheral-non-SAE, R, Mild000101
Oral Herpes-non-SAE, NR, Mild020013
Oropharyngeal Pain-non-SAE, NR, Mild020035
Oropharyngeal Pain-non-SAE, NR, Moderate000112
Osteomyelitis-non-SAE, NR, Moderate000011
Otitis Externa-non-SAE, NR, Mild010001
Otitis Media-non-SAE, NR, Mild031004
Otitis Media-non-SAE, NR, Moderate020327
Pain-non-SAE, NR, Moderate100000
Pain In Extremity-non-SAE, NR, Mild300000
Pain In Extremity-non-SAE, NR, Moderate000101
Pain In Extremity-non-SAE, R, Moderate100101
Pain In Extremity-non-SAE, R, Severe100000
Paraesthesia-non-SAE, NR, Moderate000011
Paronychia-non-SAE, NR, Mild100000
Periorbital Oedema-non-SAE, NR, Mild000011
Pharyngitis-non-SAE, NR, Mild000011
Pharyngitis-non-SAE, NR, Moderate210102
Pharyngitis Streptococcal-non-SAE, NR, Moderate020002
Pneumonia-non-SAE, NR, Moderate010023
Pneumonia Streptococcal-non-SAE, NR, Mild000011
Procedural Pain-non-SAE, NR, Moderate100123
Pyrexia-non-SAE, NR, Mild1200911
Pyrexia-non-SAE, NR, Moderate100022
Pyrexia-non-SAE, R, Mild520046
Pyrexia-non-SAE, R, Moderate100011
Rash-non-SAE, NR, Mild200000
Rash-non-SAE, R, Mild010102
Rash Erythematous-non-SAE, NR, Mild010012
Rash Macular-non-SAE, NR, Mild100000
Rash Papular-non-SAE, NR, Mild000022
Rash Pruritic-non-SAE, NR, Mild000101
Respiratory Rate Increased-non-SAE, NR, Moderate000101
Respir. Tract Infect. Viral-non-SAE, NR, Mild220002
Respir. Tract Infect Viral-non-SAE, NR, Moderate010001
Rhinitis-non-SAE, NR, Moderate000011
Rhinitis Allergic-non-SAE, NR, Mild100000
Rhinorrhoea-non-SAE, NR, Mild010102
Road Traffic Accident-non-SAE, NR, Mild010001
Scleritis-non-SAE, NR, Mild100000
Scleritis-non-SAE, NR, Moderate000011
Scoliosis-non-SAE, NR, Mild010001
Sinus Congestion-non-SAE, NR, Mild100011
Sinus Congestion-non-SAE, NR, Moderate000101
Sinus Disorder-non-SAE, NR, Severe010001
Sinus Headache-non-SAE, NR, Mild100011
Sinus Headache-non-SAE, NR, Moderate210102
Sinusitis-non-SAE, NR, Mild300134
Sinusitis-non-SAE, NR, Moderate6444315
Sinusitis-SAE, NR, Moderate100000
Sinusitis Fungal-non-SAE, NR, Moderate000011
Skin Laceration-non-SAE, NR, Mild200000
Skin Lesion-non-SAE, NR, Mild100101
Skin Papilloma-non-SAE, NR, Moderate100000
Skin Warm-non-SAE, R, Mild100000
Streptococcal Infection-non-SAE, NR, Moderate000011
Subcutaneous Abscess-non-SAE, NR, Mild001001
Suicidal Ideation-non-SAE, NR, Mild100000
Sunburn-non-SAE, NR, Severe100000
Tendonitis-non-SAE, NR, Moderate100000
Tooth Fracture-non-SAE, NR, Moderate000011
Tooth Infection-non-SAE, NR, Moderate000101
Toothache-non-SAE, NR, Moderate010012
Tourette's Disorder-non-SAE, NR, Mild010001
Upper Respir. Tract Congestion-non-SAE, NR, Mild010001
Upper Respir. Tract Infection-non-SAE, NR, Mild2335718
Upper Respir. Tract Infect.-non-SAE, NR, Moderate110135
Urinary Tract Infection-non-SAE, NR, Moderate000011
Urticaria-non-SAE, NR, Mild000022
Urticaria-non-SAE, R, Mild000011
Vaginal Lesion-non-SAE, NR, Mild010001
Vaginitis Bacterial-non-SAE, NR, Moderate001001
Varicose Vein-non-SAE, NR, Moderate000101
Varicose Vein-non-SAE, NR, Severe000011
Viral Infection-non-SAE, NR, Mild220002
Viral Infection-non-SAE, NR, Moderate300101
Viral Skin Infection-non-SAE, NR, Mild100000
Viral Upper Respir. Tract Infect-non-SAE, NR, Mild010001
Vitamin D Deficiency-non-SAE, NR, Mild100000
Vomiting-non-SAE, NR, Mild111147
Vomiting-non-SAE, NR, Moderate001001
Vomiting-non-SAE, R, Mild800112
Vomiting-non-SAE, R, Moderate100202
Vulvovaginal Candidiasis-non-SAE, NR, Mild010001
Vulvovaginal Mycotic Infection-non-SAE, NR, Mild000101
Wheezing-non-SAE, NR, Mild000011
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC- All Ages)

Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.

Time frame:
Throughout entire study (1 year and 9 months)
Reported as:
Number · AEs per infusion
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SNSC- All Ages)
AEs per infusionStudy Part 1, IV AdministrationStudy Part 2, SC AdministrationStudy Part 3a, SC AdministrationStudy Part 3b, SC AdministrationStudy Extension, SC AdministrationTotal SC (Parts 2, 3a, 3b, Extension)
Abdominal Discomfort- non-SAE, NR, Mild0.000.000.000.000.050.05
Abdominal Pain-non-SAE, NR, Mild0.000.000.000.000.050.05
Abdominal Pain-non-SAE, NR, Moderate0.000.000.000.000.050.05
Abdominal Pain Upper-non-SAE, NR, Mild0.500.000.000.000.030.03
Abdominal Pain Upper-non-SAE, R, Mild0.000.100.000.000.000.10
Acne-non-SAE, NR, Mild0.000.080.000.000.000.08
Acute Sinusitis-non-SAE, NR, Moderate0.000.080.000.000.000.08
Alopecia-non-SAE, NR, Mild0.250.000.000.000.000.00
Ammonia Increased-non-SAE, NR, Mild0.000.080.000.000.000.08
Animal Bite-non-SAE, NR, Moderate0.200.000.000.000.000.00
Anorexia-non-SAE, NR, Moderate0.000.000.170.000.000.17
Anxiety-non-SAE, NR, Mild0.000.000.000.000.030.03
Aphthous Stomatitis-non-SAE, NR, Mild0.000.080.170.000.140.14
Arthralgia-non-SAE, NR, Moderate0.000.110.000.000.000.11
Arthralgia-non-SAE, R, Mild0.250.000.170.000.000.17
Arthralgia-non-SAE, R, Moderate0.250.000.000.000.000.00
Arthritis-non-SAE, NR, Moderate0.000.000.170.000.000.17
Arthropod Bite-non-SAE, NR, Mild0.000.080.000.000.030.06
Asthenia-non-SAE, NR, Mild0.000.000.000.080.000.08
Asthma-non-SAE, NR, Mild0.000.000.000.000.040.04
Asthma-non-SAE, NR, Moderate0.250.000.170.080.030.04
Asthma-non-SAE, NR, Severe0.000.000.000.080.000.08
Asthma-non-SAE, R, Mild0.000.080.000.000.000.08
Asthma Exercise Induced-non-SAE, NR, Moderate0.000.080.000.000.000.08
ADHD-non-SAE, NR, Mild0.000.070.000.000.000.07
Back Pain-non-SAE, NR, Mild0.250.000.000.090.000.09
Back Pain-non-SAE, NR, Moderate0.250.000.000.000.000.00
Back Pain-non-SAE, R, Moderate0.200.000.000.000.000.00
Biliary Tract Infection Bacterial-SAE, NR, Moderat0.000.070.000.000.000.07
Blepharitis-non-SAE,NR, Moderate0.250.000.000.000.000.00
B.P. Diastolic Decreased-non-SAE, R, Mild0.000.000.330.000.000.33
Blood Pressure Increased-non-SAE, NR, Mild0.000.000.000.170.000.17
Blood Pressure Increased-non-SAE, R, Mild0.000.000.000.080.000.08
B.P. Systolic Increased-non-SAE, NR, Mild0.000.080.170.000.000.12
B.P. Systolic Increased-non-SAE, NR, Moderate0.000.000.000.080.000.08
B.P. Systolic Increased-non-SAE, R, Mild0.250.160.170.000.000.17
B.P. Systolic Increased-non-SAE, R, Moderate0.000.080.000.000.000.08
Breast Tenderness-non-SAE, NR, Mild0.250.000.000.000.000.00
Bronchitis-non-SAE, NR, Mild0.250.080.000.170.060.08
Bronchitis-non-SAE, NR, Moderate0.250.000.170.000.080.12
Bursitis-non-SAE, NR, Mild0.250.000.000.000.000.00
Candidiasis-non-SAE, NR, Mild0.250.000.000.000.000.00
Cardiac Murmur-non-SAE, NR, Mild0.000.080.000.000.000.08
Centrl Venous Catheterisation-non-SAE, NR, Moderat0.000.000.000.000.030.03
Cervical Spinal Stenosis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Chest Pain-non-SAE, NR, Mild0.000.000.000.000.050.05
Chest Pain-SAE, NR, Severe0.000.000.000.080.000.08
Chills-non-SAE, R, Mild0.750.000.000.000.000.00
Chills-non-SAE, R, Moderate0.500.000.000.000.000.00
C.O.P.D.-non-SAE, NR, Moderate0.000.000.000.080.000.08
C.O.P.D.-non-SAE, NR, Severe0.250.000.000.000.000.00
Chronic Sinusitis-non-SAE, NR, Mild0.000.000.170.080.030.08
Confusional State-non-SAE, R, Mild0.250.000.000.000.000.00
Conjunctival Hyperaemia-non-SAE, NR, Mild0.000.080.000.000.000.08
Conjunctivitis Allergic-non-SAE, NR, Moderate0.200.000.000.000.000.00
Conjunctivitis Infective-non-SAE, NR, Mild0.000.000.000.000.040.04
Constipation-non-SAE, NR, Mild0.250.080.000.000.030.07
Constipation-non-SAE, NR, Moderate0.000.000.000.000.030.03
Contusion-non-SAE, NR, Mild0.000.080.000.080.000.08
Contusion-non-SAE, R, Mild0.000.000.170.000.000.17
Convulsion-non-SAE, NR, Moderate0.250.000.000.000.000.00
Convulsion-SAE, NR, Moderate0.250.000.000.000.000.00
Cough-non-SAE, NR, Mild0.000.000.000.000.050.05
Cough-non-SAE, R, Mild0.250.000.000.000.000.00
Croup Infectious-non-SAE, NR, Mild0.000.080.000.080.000.08
Croup Infectious-non-SAE, NR, Moderate0.000.000.000.000.110.11
Cryptosporidiosis Infection-non-SAE, NR, Moderate0.000.000.170.000.000.17
Dental Caries-non-SAE, NR, Moderate0.000.000.000.080.000.08
Dermatitis-non-SAE, NR, Mild0.000.000.000.000.030.03
Dermatitis Contact-non-SAE, NR, Moderate0.000.000.170.000.000.17
Device Failure-non-SAE, NR, Mild0.230.000.000.000.000.00
Diarrhoea-non-SAE, NR, Mild0.250.060.000.000.050.06
Diarrhoea-non-SAE, NR, Moderate0.250.170.170.000.000.17
Diarrhoea-non-SAE, R, Mild0.000.000.000.000.050.05
Diarrhoea Haemorrhagic-non-SAE, NR,Mild0.250.000.000.000.000.00
Diarrhoea Infectious-non-SAE, NR, Moderate0.000.000.000.080.000.08
Diverticulitis-non-SAE, NR, Moderate0.200.000.000.000.000.00
Drug Eruption-non-SAE, NR, Moderate0.250.000.000.000.000.00
Dyspnoea-non-SAE, NR, Moderate0.000.000.000.000.050.05
Dyspnoea-non-SAE, R, Mild0.250.000.000.000.000.00
Ear Infection-non-SAE, NR, Moderate0.250.000.000.000.050.05
Ear Pain-non-SAE, NR, Mild0.000.060.170.000.030.06
Ear Pain-non-SAE, R, Moderate0.000.060.000.000.000.06
Eczema-non-SAE, NR, Moderate0.000.080.000.000.040.06
Eczema-non-SAE, NR, Severe0.200.000.000.000.000.00
Epistaxis-non-SAE, NR, Mild0.000.000.000.000.030.03
Epistaxis-non-SAE, NR, Moderate0.000.000.140.000.070.10
Excoriation-non-SAE, NR, Mild0.000.000.000.170.000.17
Eye Infection Viral-non-SAE, NR, Moderate0.380.100.000.080.040.08
Fall-non-SAE, NR, Moderate0.000.000.000.080.000.08
Fatigue-non-SAE, NR, Mild0.000.000.000.000.110.11
Fatigue-non-SAE, NR, Moderate0.000.000.000.000.030.03
Fatigue-non-SAE, R, Mild0.250.170.000.170.000.22
Fatigue-non-SAE, R, Moderate0.000.000.000.000.070.07
Flank Pain-non-SAE, NR, Mild0.500.000.000.000.000.00
Fungal Infection-non-SAE, NR, Moderate0.000.000.170.000.000.17
Furuncle-non-SAE, NR, Moderate0.000.080.170.000.000.12
Gastric Ulcer-non-SAE, NR, Mild0.000.000.000.090.000.09
Gastric Ulcer-non-SAE, NR, Moderate0.000.080.000.000.000.08
Gastroenteritis-non-SAE, NR, Mild0.250.000.000.080.000.08
Gastroenteritis-non-SAE, NR, Moderate0.000.000.000.080.000.08
Gastroenteritis-non-SAE, R, Mild0.250.000.000.000.000.00
Gastroenteritis Viral-non-SAE, NR, Mild0.200.060.000.000.000.06
Gastroenteritis Viral-non-SAE, NR, Moderate0.000.080.000.000.050.07
Goitre-non-SAE, NR, Mild0.250.000.000.000.000.00
Gravitational Oedema-non-SAE, R, Mild0.000.080.000.000.000.08
Haematochezia-non-SAE, NR, Mild0.000.000.000.000.030.03
Haemoglobin Decreased-non-SAE, R, Mild0.000.000.000.000.030.03
Haemorrhoids-non-SAE, NR, Mild0.000.000.000.000.040.04
Head Injury-non-SAE, NR, Mild0.000.080.000.000.000.08
Headache-non-SAE, NR, Mild0.250.130.170.080.040.07
Headache-non-SAE, NR, Moderate0.250.000.170.080.030.13
Headache-non-SAE, NR, Severe0.000.000.170.000.070.12
Headache-non-SAE, R, Mild1.100.230.170.170.110.18
Headache-non-SAE, R, Moderate0.630.070.170.000.000.24
Headache-non-SAE, R, Severe0.380.070.000.000.000.07
Heart Rate Decreased-non-SAE, R, Mild0.000.000.500.000.000.50
Heart Rate Increased-non-SAE, NR, Mild0.000.250.000.080.000.17
Heart Rate Increased-non-SAE, R, Mild0.250.080.250.080.030.08
Heart Rate Increased-non-SAE, R, Moderate0.250.000.000.000.000.00
Hiatus Hernia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Hordeolum-non-SAE, NR, Mild0.000.080.000.000.000.08
Hyperlipidaemia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Hypoxia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Implant Site Pain-non-SAE, NR, Moderate0.000.000.000.000.040.04
Infection-non-SAE, NR, Mild0.500.000.000.000.050.05
Infection-non-SAE, NR, Moderate0.200.080.000.000.000.08
Influenza-non-SAE, NR, Mild0.250.080.000.000.030.08
Influenza-non-SAE, NR, Moderate0.200.070.000.000.040.06
Infusion Related Reaction-non-SAE, R, Mild0.250.080.000.000.000.08
Infusion Site Erythema-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Haematoma-non-SAE, NR, Mild0.000.000.000.080.030.06
Infusion Site Haematoma-non-SAE, R, Mild0.000.070.170.170.040.08
Infusion Site Haematoma-non-SAE, R, Moderate0.000.000.000.000.040.04
Infusion Site Haemorrhage-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Irritation-non-SAE, R, Mild0.250.100.000.000.050.07
Infusion Site Oedema-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Pain-non-SAE, R, Mild0.200.140.150.080.040.16
Infusion Site Pain-non-SAE, R, Moderate0.000.070.170.160.000.16
Infusion Site Pruritus-non-SAE, NR, Moderate0.000.070.000.000.000.07
Infusion Site Pruritus-non-SAE, R, Mild0.000.070.170.080.000.08
Infusion Site Pruritus-non-SAE, R, Moderate0.000.070.000.000.000.07
Infusion Site Rash-non-SAE, NR, Mild0.000.060.000.000.000.06
Infusion Site Rash-non-SAE, R, Mild0.000.080.170.000.030.08
Infusion Site Reaction-non-SAE, R, Mild0.000.000.000.090.000.09
Infusion Site Swelling-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Swelling-non-SAE, R, Moderate0.000.000.170.000.000.17
Infusion Site Vesicles-non-SAE, R, Mild0.000.080.000.000.000.08
Inguinal Mass-non-SAE, NR, Mild0.000.080.000.000.000.08
Injection Site Haematoma-non-SAE, NR, Mild0.000.000.000.080.000.08
Insomnia-non-SAE, NR, Mild0.000.070.000.000.030.03
Insomnia-non-SAE, NR, Moderate0.000.000.000.080.000.08
Intermit. Explosive Disorder-non-SAE, NR, Moderate0.000.000.000.080.000.08
Irritability-non-SAE, NR, Mild0.000.000.000.000.130.13
Irritable Bowel Syndrome-non-SAE, NR, Moderate0.000.060.000.080.040.06
Joint Dislocation-non-SAE, NR, Moderate0.000.000.000.080.000.08
Laryngitis-non-SAE, NR, Mild0.000.000.170.000.000.17
Laryngitis-non-SAE, NR, Moderate0.000.000.170.000.000.17
Lethargy-non-SAE, NR, Mild0.000.000.000.000.070.07
Limb Injury-non-SAE, NR, Mild0.000.000.000.080.000.08
Lip Ulceration-non-SAE, NR, Mild0.000.000.000.000.030.03
Livedo Reticularis-non-SAE, R, Mild0.250.000.000.000.000.00
Lung Infection-non-SAE, NR, Moderate0.250.000.000.000.000.00
Lung Infection-non-SAE, NR, Severe0.250.000.000.000.000.00
Lymphadenopathy-non-SAE, NR, Mild0.250.000.000.000.040.04
Malaise-non-SAE, NR, Moderate0.250.000.000.080.000.08
Malaise-non-SAE, R, Moderate0.000.100.000.000.000.10
Middle Ear Effusion-non-SAE, NR, Moderate0.250.000.000.000.000.00
Migraine-non-SAE, NR, Mild0.000.000.000.080.030.06
Migraine-non-SAE, NR, Severe0.200.000.000.000.000.00
Migraine-non-SAE, R, Severe0.000.000.000.000.070.07
Mouth Ulceration-non-SAE, NR, Mild0.250.000.000.000.000.00
Muscular Weakness-non-SAE, NR, Moderate0.000.000.000.080.000.08
Musculoskeletal Chest Pain-non-SAE, NR, Mild0.000.000.000.090.000.09
Musculoskeletal Pain-non-SAE, NR, Mild0.000.000.000.080.000.08
Musculoskeletal Pain-non-SAE, NR, Moderate0.000.000.170.070.040.07
Myalgia-non-SAE, NR, Mild0.000.080.170.080.090.9
Myalgia-non-SAE, NR, Moderate0.000.000.000.080.000.08
Myopia-non-SAE, NR, Mild0.000.100.000.000.000.10
Nasal Congestion-non-SAE, NR, Mild0.000.000.000.000.070.07
Nasal Congestion-non-SAE, NR, Moderate0.000.000.170.000.000.17
Nasal Disorder-non-SAE, NR, Mild0.000.070.000.000.000.07
Nasal Mucosal Disorder-non-SAE, NR, Mild0.000.000.000.080.000.08
Nasal Polyps-non-SAE, NR, Moderate0.000.000.000.080.000.08
Nasopharyngitis-non-SAE, NR, Mild0.250.000.000.080.040.05
Nasopharyngitis-non-SAE, NR, Moderate0.000.080.000.070.060.07
Nausea-non-SAE, NR, Mild0.250.070.000.080.070.08
Nausea-non-SAE, NR, Moderate0.000.070.000.170.030.07
Nausea-non-SAE, NR, Severe0.000.000.000.000.070.07
Nausea-non-SAE, R, Mild0.750.000.000.270.000.27
Oedema Peripheral-non-SAE, R, Mild0.000.000.000.080.000.08
Oral Herpes-non-SAE, NR, Mild0.000.080.000.000.030.07
Oropharyngeal Pain-non-SAE, NR, Mild0.000.080.000.000.070.07
Oropharyngeal Pain-non-SAE, NR, Moderate0.000.000.000.080.070.08
Osteomyelitis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Otitis Externa-non-SAE, NR, Mild0.000.080.000.000.000.08
Otitis Media-non-SAE, NR, Mild0.000.130.170.000.000.17
Otitis Media-non-SAE, NR, Moderate0.000.170.000.130.110.14
Pain-non-SAE, NR, Moderate0.250.000.000.000.000.00
Pain In Extremity-non-SAE, NR, Mild0.380.000.000.000.000.00
Pain In Extremity-non-SAE, NR, Moderate0.000.000.000.080.000.08
Pain In Extremity-non-SAE, R, Moderate0.250.000.000.080.000.08
Pain In Extremity-non-SAE, R, Severe0.250.000.000.000.000.00
Paraesthesia-non-SAE, NR, Moderate0.000.000.000.000.030.03
Paronychia-non-SAE, NR, Mild0.250.000.000.000.000.00
Periorbital Oedema-non-SAE, NR, Mild0.000.000.000.000.070.07
Pharyngitis-non-SAE, NR, Mild0.000.000.000.000.050.05
Pharyngitis-non-SAE, NR, Moderate0.500.080.000.080.000.08
Pharyngitis Streptococcal-non-SAE, NR, Moderate0.000.080.000.000.000.08
Pneumonia-non-SAE, NR, Moderate0.000.080.000.000.040.06
Pneumonia Streptococcal-non-SAE, NR, Mild0.000.000.000.000.070.07
Procedural Pain-non-SAE, NR, Moderate0.250.000.000.080.040.04
Pyrexia-non-SAE, NR, Mild0.250.060.000.000.120.07
Pyrexia-non-SAE, NR, Moderate0.250.000.000.000.030.03
Pyrexia-non-SAE, R, Mild0.630.170.000.000.070.07
Pyrexia-non-SAE, R, Moderate0.250.000.000.000.030.03
Rash-non-SAE, NR, Mild0.250.000.000.000.000.00
Rash-non-SAE, R, Mild0.000.080.000.080.000.08
Rash Erythematous-non-SAE, NR, Mild0.000.080.000.000.050.07
Rash Macular-non-SAE, NR, Mild0.250.000.000.000.000.00
Rash Papular-non-SAE, NR, Mild0.000.000.000.000.030.03
Rash Pruritic-non-SAE, NR, Mild0.000.000.000.080.000.08
Respiratory Rate Increased-non-SAE, NR, Moderate0.000.000.000.080.000.08
Respir. Tract Infect. Viral-non-SAE, NR, Mild0.250.170.000.000.000.17
Respir. Tract Infect Viral-non-SAE, NR, Moderate0.000.080.000.000.000.08
Rhinitis-non-SAE, NR, Moderate0.000.000.000.000.090.09
Rhinitis Allergic-non-SAE, NR, Mild0.250.000.000.000.000.00
Rhinorrhoea-non-SAE, NR, Mild0.000.080.000.080.000.08
Road Traffic Accident-non-SAE, NR, Mild0.000.070.000.000.000.07
Scleritis-non-SAE, NR, Mild0.200.000.000.000.000.00
Scleritis-non-SAE, NR, Moderate0.000.000.000.000.040.04
Scoliosis-non-SAE, NR, Mild0.000.080.000.000.000.08
Sinus Congestion-non-SAE, NR, Mild0.200.000.000.000.040.04
Sinus Congestion-non-SAE, NR, Moderate0.000.000.000.080.000.08
Sinus Disorder-non-SAE, NR, Severe0.000.060.000.000.000.06
Sinus Headache-non-SAE, NR, Mild0.200.000.000.000.040.04
Sinus Headache-non-SAE, NR, Moderate0.500.070.000.080.000.08
Sinusitis-non-SAE, NR, Mild0.460.000.000.080.040.04
Sinusitis-non-SAE, NR, Moderate0.250.070.170.080.040.08
Sinusitis-SAE, NR, Moderate0.200.000.000.000.000.00
Sinusitis Fungal-non-SAE, NR, Moderate0.000.000.000.000.070.07
Skin Laceration-non-SAE, NR, Mild0.500.000.000.000.000.00
Skin Lesion-non-SAE, NR, Mild0.250.000.000.080.000.08
Skin Papilloma-non-SAE, NR, Moderate0.200.000.000.000.000.00
Skin Warm-non-SAE, R, Mild0.250.000.000.000.000.00
Streptococcal Infection-non-SAE, NR, Moderate0.000.000.000.000.030.03
Subcutaneous Abscess-non-SAE, NR, Mild0.000.000.170.000.000.17
Suicidal Ideation-non-SAE, NR, Mild0.200.000.000.000.000.00
Sunburn-non-SAE, NR, Severe0.250.000.000.000.000.00
Tendonitis-non-SAE, NR, Moderate0.250.000.000.000.000.00
Tooth Fracture-non-SAE, NR, Moderate0.000.000.000.000.040.04
Tooth Infection-non-SAE, NR, Moderate0.000.000.000.080.000.08
Toothache-non-SAE, NR, Moderate0.000.070.000.000.030.05
Tourette's Disorder-non-SAE, NR, Mild0.000.070.000.000.000.07
Upper Respir. Tract Congestion-non-SAE, NR, Mild0.000.080.000.000.000.08
Upper Respir. Tract Infection-non-SAE, NR, Mild0.230.080.170.080.060.08
Upper Respir. Tract Infect.-non-SAE, NR, Moderate0.250.080.000.080.050.07
Urinary Tract Infection-non-SAE, NR, Moderate0.000.000.000.000.040.04
Urticaria-non-SAE, NR, Mild0.000.000.000.000.050.05
Urticaria-non-SAE, R, Mild0.000.000.000.000.070.07
Vaginal Lesion-non-SAE, NR, Mild0.000.080.000.000.000.08
Vaginitis Bacterial-non-SAE, NR, Moderate0.000.000.170.000.000.17
Varicose Vein-non-SAE, NR, Moderate0.000.000.000.080.000.08
Varicose Vein-non-SAE, NR, Severe0.000.000.000.000.040.04
Viral Infection-non-SAE, NR, Mild0.250.080.000.000.000.08
Viral Infection-non-SAE, NR, Moderate0.380.000.000.080.000.08
Viral Skin Infection-non-SAE, NR, Mild0.250.000.000.000.000.00
Viral Upper Respir. Tract Infect-non-SAE, NR, Mild0.000.080.000.000.000.08
Vitamin D Deficiency-non-SAE, NR, Mild0.250.000.000.000.000.00
Vomiting-non-SAE, NR, Mild0.250.070.170.080.040.07
Vomiting-non-SAE, NR, Moderate0.000.000.170.000.000.17
Vomiting-non-SAE, R, Mild0.750.000.000.090.050.07
Vomiting-non-SAE, R, Moderate0.250.000.000.180.000.18
Vulvovaginal Candidiasis-non-SAE, NR, Mild0.000.080.000.000.000.08
Vulvovaginal Mycotic Infection-non-SAE, NR, Mild0.000.000.000.080.000.08
Wheezing-non-SAE, NR, Mild0.000.000.000.000.090.09
SecondaryNumber of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)

Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR

Time frame:
Throughout entire study (1 year and 9 months)
Reported as:
Number · Adverse events
Number of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)
Adverse eventsStudy Part 1, IV AdministrationStudy Part 2, SC AdministrationStudy Part 3a, SC AdministrationStudy Part 3b, SC AdministrationStudy Extension, SC AdministrationTotal SC (Parts 2, 3a, 3b, Extension)
Abdominal Discomfort- non-SAE, NR, Mild000011
Abdominal Distension-non-SAE, NR, Mild000077
Abdominal Distension-non-SAE, NR, Moderate000224
Abdominal Distension-non-SAE, R, Mild010102
Abdominal Distension-non-SAE, R, Moderate010001
Abdominal Pain-non-SAE, NR, Mild101001
Abdominal Pain Upper-non-SAE, NR, Mild000044
Abdominal Pain Upper-non-SAE, NR, Moderate000022
Abdominal Pain Upper-non-SAE, R, Mild001001
Abdominal Tenderness-non-SAE, NR, Mild000101
Acne-non-SAE, NR, Moderate000101
Addison's Disease-non-SAE, NR, Mild010001
Addison's Disease-non-SAE, NR, Moderate100000
Arthralgia-non-SAE, NR, Moderate011215
Arthralgia-non-SAE, NR, Severe000011
Asthenia-non-SAE, NR, Moderate001001
Back Pain-non-SAE, NR, Mild000101
Back Pain-non-SAE, NR, Moderate000202
Blepharitis-non-SAE,NR, Mild001001
Breath Sounds Abnormal-non-SAE, NR, Mild100000
Bronchitis-non-SAE, NR, Moderate000022
Chronic Sinusitis-non-SAE, NR, Mild000101
Chronic Sinusitis-non-SAE, NR, Moderate000011
Conjunctivitis Bacterial-non-SAE, NR, Moderate001001
Conjunctivitis Infective-non-SAE, NR, Moderate000011
Costochondritis-non-SAE, NR, Moderate010001
Costochondritis-non-SAE, NR, Severe010001
Cough-non-SAE, NR, Mild200000
Cystitis-non-SAE, NR, Moderate000011
Dermatitis-non-SAE, NR, Moderate100000
Dermatitis Contact-non-SAE, NR, Moderate110102
Diarrhoea-non-SAE, NR, Mild010214
Diarrhoea-non-SAE, NR, Moderate100101
Diarrhoea-non-SAE, R, Mild002002
Dyspepsia-non-SAE, NR, Moderate010001
Dyspnoea-non-SAE, NR, Mild001001
Ear Pain-non-SAE, NR, Mild100011
Exostosis-non-SAE, NR,Mild001001
Eye Infection Viral-non-SAE, NR, Moderate000101
Eye Irritation-non-SAE, R, Mild000011
Eye Oedema-non-SAE, NR, Mild010001
Fatigue-non-SAE, R, Mild010001
Flatulence-non-SAE, NR, Mild000011
Flatulence-non-SAE, NR, Moderate000101
Folliculitis-non-SAE, NR, Moderate100000
Gastroenteritis Viral-non-SAE, NR, Mild100000
Headache-non-SAE, NR, Mild121104
Headache-non-SAE, R, Mild020002
Infection-non-SAE, NR, Moderate001012
Influenza-non-SAE, NR, Moderate100101
Infusion Site Haematoma-non-SAE, R, Mild000011
Infusion Site Haemorrhage-non-SAE, R, Mild010001
Infusion Site Oedema-non-SAE, R, Mild010001
Infusion Site Pain-non-SAE, R, Mild010001
Infusion Site Pruritus-non-SAE, R, Mild010001
Injection Site Haematoma-non-SAE, R, Mild010001
Injection Site Pain-non-SAE, NR, Mild000011
Joint Sprain-non-SAE, NR, Mild020002
Joint Swelling-non-SAE, NR, Mild010001
Joint Swelling-non-SAE, NR, Moderate010001
Laryngitis Viral-non-SAE, NR, Moderate000011
Limb Injury-non-SAE, NR, Mild100000
Lymphadenopathy-non-SAE, NR, Mild101001
Memory Impairment-non-SAE, NR, Moderate001001
Migraine-non-SAE, NR, Moderate000011
Migraine-non-SAE, R, Moderate000011
Muscle Strain-non-SAE, NR, Mild001012
Nasal Congestion-non-SAE, NR, Mild000011
Nasal Congestion-non-SAE, NR, Moderate000011
Nasopharyngitis-non-SAE, NR, Mild210023
Nasopharyngitis-non-SAE, NR, Moderate000022
Nausea-non-SAE, NR, Mild011147
Nausea-non-SAE, R, Mild011013
Nausea-non-SAE, R, Moderate100000
Oedema Peripheral-non-SAE, NR, Moderate010001
Oral Herpes-non-SAE, NR, Mild010001
Oropharyngeal Pain-non-SAE, NR, Mild100000
Oropharyngeal Pain-non-SAE, NR, Moderate200011
Osteopenia-non-SAE, NR, Moderate010001
Pain In Extremity-non-SAE, NR, Moderate000001
Pharyngitis-non-SAE, NR, Mild010001
Pharyngitis-non-SAE, NR, Moderate000101
Pneumonia-non-SAE, NR, Mild000101
Pneumonia Bacterial-non-SAE, NR, Moderate001001
Pyrexia-non-SAE, NR, Mild010012
Rales-non-SAE, NR, Moderate100000
Respir. Tract Infect. Viral-non-SAE, NR, Mild000011
Respir. Tract Infect Viral-non-SAE, NR, Moderate100000
Sinusitis-non-SAE, NR, Mild000011
Sinusitis-non-SAE, NR, Moderate102103
Sports Injury-non-SAE, NR, Mild010001
Upper Respir. Tract Infection-non-SAE, NR, Mild200112
Upper Respir. Tract Infect.-non-SAE, NR, Moderate100000
Urinary Tract Infection-non-SAE, NR, Moderate100000
Vestibulitis-non-SAE, NR, Moderate000101
Viral Up. Respir Tract Infec-non-SAE, NR, Moderate000101
Vomiting-non-SAE, NR, Mild100000
Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate000011
Wound-non-SAE, NR, Moderate000101
SecondaryRate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)

Seriousness and causality are abbreviated below as: Seriousness: Serious Adverse Event= SAE, non-Serious Adverse Event= non-SAE Causality: possibly or probably related= R, not related= NR Rate of AEs defined as the number of AEs categorized by MedDRA preferred terms, seriousness, severity, and causality divided by the number of infusions.

Time frame:
Throughout entire study (1 year and 9 months)
Reported as:
Number · AEs per infusion
Rate of All AEs Categorized by MedDRA Preferred Terms, Seriousness, Severity, and Causality (SESC)
AEs per infusionStudy Part 1, IV AdministrationStudy Part 2, SC AdministrationStudy Part 3a, SC AdministrationStudy Part 3b, SC AdministrationStudy Extension, SC AdministrationTotal SC (Parts 2, 3a, 3b, Extension)
Abdominal Discomfort- non-SAE, NR, Mild0.000.000.000.000.040.04
Abdominal Distension-non-SAE, NR, Mild0.000.000.000.000.290.29
Abdominal Distension-non-SAE, NR, Moderate0.000.000.000.170.080.13
Abdominal Distension-non-SAE, R, Mild0.000.000.000.080.000.08
Abdominal Distension-non-SAE, R, Moderate0.000.080.000.000.000.08
Abdominal Pain-non-SAE, NR, Mild0.250.000.170.000.000.17
Abdominal Pain Upper-non-SAE, NR, Mild0.000.000.000.000.170.17
Abdominal Pain Upper-non-SAE, NR, Moderate0.000.000.000.000.080.08
Abdominal Pain Upper-non-SAE, R, Mild0.000.000.170.000.000.17
Abdominal Tenderness-non-SAE, NR, Mild0.000.000.000.080.000.08
Acne-non-SAE, NR, Moderate0.000.000.000.080.000.08
Addison's Disease-non-SAE, NR, Mild0.000.080.000.000.000.08
Addison's Disease-non-SAE, NR, Moderate0.200.000.000.000.000.00
Arthralgia-non-SAE, NR, Moderate0.000.080.170.170.040.13
Arthralgia-non-SAE, NR, Severe0.000.000.000.000.040.04
Asthenia-non-SAE, NR, Moderate0.000.000.170.000.000.17
Back Pain-non-SAE, NR, Mild0.000.000.000.080.000.08
Back Pain-non-SAE, NR, Moderate0.000.000.000.170.000.17
Blepharitis-non-SAE,NR, Mild0.000.000.170.000.000.17
Breath Sounds Abnormal-non-SAE, NR, Mild0.200.000.000.000.000.00
Bronchitis-non-SAE, NR, Moderate0.000.000.000.000.070.07
Chronic Sinusitis-non-SAE, NR, Mild0.000.000.000.080.000.08
Chronic Sinusitis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Conjunctivitis Bacterial-non-SAE, NR, Moderate0.000.000.170.000.000.17
Conjunctivitis Infective-non-SAE, NR, Moderate0.000.000.000.000.030.03
Costochondritis-non-SAE, NR, Moderate0.000.080.000.000.000.08
Costochondritis-non-SAE, NR, Severe0.000.080.000.000.000.08
Cough-non-SAE, NR, Mild0.500.000.000.000.000.00
Cystitis-non-SAE, NR, Moderate0.000.000.000.000.030.03
Dermatitis-non-SAE, NR, Moderate0.250.000.000.000.000.00
Dermatitis Contact-non-SAE, NR, Moderate0.250.080.000.080.000.08
Diarrhoea-non-SAE, NR, Mild0.000.080.000.170.040.08
Diarrhoea-non-SAE, NR, Moderate0.250.000.000.080.000.08
Diarrhoea-non-SAE, R, Mild0.000.000.330.000.000.33
Dyspepsia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Dyspnoea-non-SAE, NR, Mild0.000.000.170.000.000.17
Ear Pain-non-SAE, NR, Mild0.250.000.000.000.040.04
Exostosis-non-SAE, NR,Mild0.000.000.170.000.000.17
Eye Infection Viral-non-SAE, NR, Moderate0.000.000.000.080.000.08
Eye Irritation-non-SAE, R, Mild0.000.000.000.000.040.04
Eye Oedema-non-SAE, NR, Mild0.000.080.000.000.000.08
Fatigue-non-SAE, R, Mild0.000.080.000.000.000.08
Flatulence-non-SAE, NR, Mild0.000.000.000.000.040.04
Flatulence-non-SAE, NR, Moderate0.000.000.000.080.000.08
Folliculitis-non-SAE, NR, Moderate0.250.000.000.000.000.00
Gastroenteritis Viral-non-SAE, NR, Mild0.250.000.000.000.000.00
Headache-non-SAE, NR, Mild0.200.170.170.080.000.17
Headache-non-SAE, R, Mild0.000.160.000.000.000.16
Infection-non-SAE, NR, Moderate0.000.000.170.000.040.10
Influenza-non-SAE, NR, Moderate0.250.000.000.080.000.08
Infusion Site Haematoma-non-SAE, R, Mild0.000.000.000.000.040.04
Infusion Site Haemorrhage-non-SAE, R, Mild0.000.070.000.000.000.07
Infusion Site Oedema-non-SAE, R, Mild0.000.080.000.000.000.08
Infusion Site Pain-non-SAE, R, Mild0.000.080.000.000.000.00
Infusion Site Pruritus-non-SAE, R, Mild0.000.080.000.000.000.08
Injection Site Haematoma-non-SAE, R, Mild0.000.080.000.000.000.08
Injection Site Pain-non-SAE, NR, Mild0.000.000.000.000.040.04
Joint Sprain-non-SAE, NR, Mild0.000.170.000.000.000.17
Joint Swelling-non-SAE, NR, Mild0.000.080.000.000.000.08
Joint Swelling-non-SAE, NR, Moderate0.000.080.000.000.000.08
Laryngitis Viral-non-SAE, NR, Moderate0.000.000.000.000.030.03
Limb Injury-non-SAE, NR, Mild0.250.000.000.000.000.00
Lymphadenopathy-non-SAE, NR, Mild0.250.000.170.000.000.17
Memory Impairment-non-SAE, NR, Moderate0.000.000.170.000.000.17
Migraine-non-SAE, NR, Moderate0.000.000.000.000.040.04
Migraine-non-SAE, R, Moderate0.000.000.000.000.040.04
Muscle Strain-non-SAE, NR, Mild0.000.000.170.000.030.10
Nasal Congestion-non-SAE, NR, Mild0.000.000.000.000.040.04
Nasal Congestion-non-SAE, NR, Moderate0.000.000.000.000.040.04
Nasopharyngitis-non-SAE, NR, Mild0.250.080.000.000.040.04
Nasopharyngitis-non-SAE, NR, Moderate0.000.000.000.000.070.07
Nausea-non-SAE, NR, Mild0.000.080.170.080.170.13
Nausea-non-SAE, R, Mild0.000.080.170.000.040.08
Nausea-non-SAE, R, Moderate0.250.000.000.000.000.00
Oedema Peripheral-non-SAE, NR, Moderate0.000.080.000.000.000.08
Oral Herpes-non-SAE, NR, Mild0.000.080.000.000.000.08
Oropharyngeal Pain-non-SAE, NR, Mild0.200.000.000.000.000.00
Oropharyngeal Pain-non-SAE, NR, Moderate0.230.000.000.000.030.03
Osteopenia-non-SAE, NR, Moderate0.000.080.000.000.000.08
Pain In Extremity-non-SAE, NR, Moderate0.000.000.170.000.000.17
Pharyngitis-non-SAE, NR, Mild0.000.080.000.000.000.08
Pharyngitis-non-SAE, NR, Moderate0.000.000.000.080.000.08
Pneumonia-non-SAE, NR, Mild0.000.000.000.080.000.08
Pneumonia Bacterial-non-SAE, NR, Moderate0.000.000.170.000.000.17
Pyrexia-non-SAE, NR, Mild0.000.080.000.000.040.06
Rales-non-SAE, NR, Moderate0.250.000.000.000.000.00
Respir. Tract Infect. Viral-non-SAE, NR, Mild0.000.000.000.000.030.03
Respir. Tract Infect Viral-non-SAE, NR, Moderate0.250.000.000.000.000.00
Sinusitis-non-SAE, NR, Mild0.000.000.000.000.040.04
Sinusitis-non-SAE, NR, Moderate0.250.000.170.080.000.17
Sports Injury-non-SAE, NR, Mild0.000.080.000.000.000.08
Upper Respir. Tract Infection-non-SAE, NR, Mild0.250.000.000.080.030.06
Upper Respir. Tract Infect.-non-SAE, NR, Moderate0.250.000.000.000.000.00
Urinary Tract Infection-non-SAE, NR, Moderate0.250.000.000.000.000.00
Vestibulitis-non-SAE, NR, Moderate0.000.000.000.080.000.08
Viral Up. Respir Tract Infec-non-SAE, NR, Moderate0.000.000.000.080.000.08
Vomiting-non-SAE, NR, Mild0.250.000.000.000.000.00
Vulvovaginal Mycotic Infect.-non-SAE, NR, Moderate0.000.000.000.000.030.03
Wound-non-SAE, NR, Moderate0.000.000.000.080.000.08
SecondaryPercentage of Infusions Associated With ≥1 AE Related to the Study Drug
Time frame:
Throughout the study period (1 year and 9 months)
Reported as:
Number · Percentage of infusions
Percentage of Infusions Associated With ≥1 AE Related to the Study Drug
Percentage of infusionsFSDSSNSCSESC
Study Part 1 (IV) (Units Analyzed N= 207, 162, 45)22.227.82.2
Study Part 2 (SC) (N = 595, 469, 126)9.910.28.7
Study Part 3a (SC) (N = 268, 206, 62)7.88.36.5
Study Part 3b (SC) (N = 538, 418, 120)3.54.30.8
Study Extension (SC) (N = 893, 664, 229)3.13.81.3
Total SC (N = 2294, 1757, 537)5.56.13.5
SecondaryPercentage of Infusions Associated With ≥1 AEs That Begin During Infusion or Within 72 Hours of Completion of Infusion
Time frame:
During Infusion or Within 72 Hours of Completion of Infusions
Reported as:
Number · Percentage of infusions
Percentage of Infusions Associated With ≥1 AEs That Begin During Infusion or Within 72 Hours of Completion of Infusion
Percentage of infusionsFSDSSNSCSESC
Study Part 1 (IV) (Units Analyzed N= 207, 162, 45)30.935.813.3
Study Part 2 (SC) (N = 595, 469, 126)15.015.811.9
Study Part 3a (SC) (N = 268, 206, 62)11.612.68.1
Study Part 3b (SC) (N = 538, 418, 120)8.78.98.3
Study Extension (SC) (N = 893, 664, 229)9.410.56.1
Total SC (N = 2294, 1757, 537)10.911.88.2
SecondaryPercentage of Infusions Associated With ≥1 AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Time frame:
During Infusion or Within 72 Hours of Completion of Infusions
Reported as:
Number · Percentage of infusions
Percentage of Infusions Associated With ≥1 AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Percentage of infusionsFSDSSNSCSESC
Study Part 1 (IV) (Units Analyzed N= 207, 162, 45)28.532.713.3
Study Part 2 (SC) (N = 595, 469, 126)11.812.210.3
Study Part 3a (SC) (N = 268, 206, 62)10.111.26.5
Study Part 3b (SC) (N = 538, 418, 120)7.27.27.5
Study Extension (SC) (N = 893, 664, 229)7.38.14.8
Total SC (N = 2294, 1757, 537)8.89.36.9
SecondaryPercentage of Infusions Associated With ≥1 Systemic AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Time frame:
During Infusion or Within 72 Hours of Completion of Infusions
Reported as:
Number · Percentage of infusions
Percentage of Infusions Associated With ≥1 Systemic AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Percentage of infusionsFSDSSNSCSESC
Study Part 1 (IV) (Units Analyzed N= 207, 162, 45)28.032.113.3
Study Part 2 (SC) (N = 595, 469, 126)7.67.77.1
Study Part 3a (SC) (N = 268, 206, 62)7.88.36.5
Study Part 3b (SC) (N = 538, 418, 120)6.15.77.5
Study Extension (SC) (N = 893, 664, 229)6.36.94.4
Total SC (N = 2294, 1757, 537)6.87.06.0
PrimaryPercentage of Participants With Prior Experience With Subcutaneous Administration of Immunoglobulins (SESC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of participants for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

Time frame:
Throughout study (1 year and 9 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Prior Experience With Subcutaneous Administration of Immunoglobulins (SESC) Who Had Any Infusion for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Percentage of ParticipantsInfusion Rate Change - For Any ReasonInfusion Rate Change - For Tolerability/AE
Study Part 1 (IV) (n= 11)0.00.00
Study Part 2 (SC) (n= 11)18.20.00
Study Part 3A (SC) (n=10)0.000.00
Study Part 3B (SC) (n=10)0.000.00
Study Extension (SC) (n= 9)11.10.00
Study Part 2, 3A, 3B, Study Extension (n= 11)18.20.00
PrimaryPercentage of Infusions in FSDS for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

Time frame:
Throughout study (1 year and 9 months)
Reported as:
Number · Percentage of Infusions
Percentage of Infusions in FSDS for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Percentage of InfusionsInfusion Rate Change (Percentage) - For Any ReasonInfusion Rate Change - For Tolerability/AE
Study Part 1 (IV) (n= 207 Infusions)6.7 (3.6 to 11.3)6.2 (3.2 to 10.5)
Study Part 2 (SC) (n= 595 Infusions)4.2 (2.7 to 6.2)0.5 (0.1 to 1.3)
Study Part 3A (SC) (n=268 Infusions)3.1 (1.4 to 5.8)0.4 (0.0 to 1.7)
Study Part 3B (SC) (n=538 Infusions)1.1 (0.4 to 2.3)0.2 (0.0 to 0.8)
Study Extension (SC) (n= 893 Infusions)0.6 (0.2 to 1.2)0.0 (NA to NA)
Parts 2, 3A, 3B, & Extension (n= 2,294 Infusions)1.9 (1.4 to 2.5)0.2 (0.1 to 0.5)
PrimaryPercentage of Infusions in SNSC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

Time frame:
Throughout study (1 year and 9 months)
Reported as:
Number · Percentage of Infusions
Percentage of Infusions in SNSC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Percentage of InfusionsInfusion Rate Change (Percentage) - For Any ReasonInfusion Rate Change - For Tolerability/AE
Study Part 1 (IV) (n= 162 Infusions)8.7 (4.7 to 14.8)8.0 (4.2 to 13.8)
Study Part 2 (SC) (n= 469 Infusions)4.5 (2.8 to 6.8)0.6 (0.2 to 1.7)
Study Part 3A (SC) (n=206 Infusions)4.0 (1.8 to 7.7)0.5 (0.0 to 2.2)
Study Part 3B (SC) (n=418 Infusions)1.5 (0.6 to 3.0)0.2 (0.0 to 1.1)
Study Extension (SC) (n= 664 Infusions)0.6 (0.2 to 1.4)0.0 (NA to NA)
Parts 2, 3A, 3B, & Extension (n= 1,757 Infusions)2.2 (1.6 to 3.0)0.3 (0.1 to 0.6)
PrimaryPercentage of Infusions in SESC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped

Ability to tolerate IGIV, 10% administered IV or SC. Measured as the percentage of infusions for which the infusion rate was reduced at any infusion and/or the infusion was interrupted or stopped for (i) any reason and (ii) for tolerability concerns or AEs

Time frame:
Throughout study (1 year and 9 months)
Reported as:
Number · Percentage of Infusions
Percentage of Infusions in SESC for Which the Infusion Rate Was Reduced and/or the Infusion Was Interrupted or Stopped
Percentage of InfusionsInfusion Rate Change (Percentage) - For Any ReasonInfusion Rate Change - For Tolerability/AE
Study Part 1 (IV) (n= 45 Infusions)0.0 (NA to NA)0.0 (NA to NA)
Study Part 2 (SC) (n= 126 Infusions)3.3 (1.0 to 7.8)0.0 (NA to NA)
Study Part 3A (SC) (n=62 Infusions)0.0 (NA to NA)0.0 (NA to NA)
Study Part 3B (SC) (n=120 Infusions)0.0 (NA to NA)0.0 (NA to NA)
Study Extension (SC) (n= 229 Infusions)0.4 (0.0 to 1.9)0.0 (NA to NA)
Parts 2, 3A, 3B, & Extension (n= 537 Infusions)0.9 (0.3 to 2.0)0.0 (NA to NA)
SecondaryPercentage of Infusions Associated With ≥1 Local AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Time frame:
During Infusion or Within 72 Hours of Completion of Infusions
Reported as:
Number · Percentage of infusions
Percentage of Infusions Associated With ≥1 Local AE Excluding Infections That Begin During Infusion or Within 72 Hours of Completion of Infusion.
Percentage of infusionsFSDSSNSCSESC
Study Part 1 (IV) (Units Analyzed N= 207, 162, 45)1.01.20.0
Study Part 2 (SC) (N = 595, 469, 126)4.95.14.0
Study Part 3a (SC) (N = 268, 206, 62)2.22.90.0
Study Part 3b (SC) (N = 538, 418, 120)1.51.90.0
Study Extension (SC) (N = 893, 664, 229)1.11.40.4
Total SC (N = 2294, 1757, 537)2.32.71.1

Adverse events

Collected over Throughout the entire study period (1 year, 9 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IV Treatment Period—2/49 (4.1%)38/49 (77.6%)
SC Treatment Period—2/48 (4.2%)44/47 (93.6%)
Most frequent serious events
Most frequent serious events
EventIV Treatment PeriodSC Treatment Period
Biliary Tract Infection BacterialInfections and infestations0/491/48
Chest painGeneral disorders0/491/48
SinusitisInfections and infestations1/490/48
Convulsion/seizureNervous system disorders1/490/48
Most frequent other events
Showing 10 of 35
Most frequent other events
EventIV Treatment PeriodSC Treatment Period
HEADACHENervous system disorders17/4923/47
PYREXIAGeneral disorders5/4914/47
INFUSION SITE PAINGeneral disorders1/4910/47
NAUSEAGastrointestinal disorders5/498/47
VOMITINGGastrointestinal disorders7/497/47
FATIGUEGeneral disorders1/497/47
CHILLSGeneral disorders7/490/47
ASTHMARespiratory, thoracic and mediastinal disorders3/496/47
OROPHARYNGEAL PAINRespiratory, thoracic and mediastinal disorders1/496/47
ABDOMINAL PAIN UPPERGastrointestinal disorders1/495/47

Baseline characteristics

Age, Customized
Age, Customized(Participants)Treated Participants
2 to <12 years14
≥ 12 years35
Sex: Female, Male
Sex: Female, Male(Participants)Treated Participants
Female22
Male27
Region of Enrollment
Region of Enrollment(Participants)Treated Participants
United States49
08

Study locations

9 sites
  • Los Angeles, California, United States
  • Centennial, Colorado, United States
  • North Palm Beach, Florida, United States
  • Atlanta, Georgia, United States
  • Durham, North Carolina, United States
  • Cleveland, Ohio, United States
  • Dallas, Texas, United States
  • Galveston, Texas, United States
  • Milwaukee, Wisconsin, United States
09

References and documents

Publications

  • Neu AM, Warady BA, Furth SL, Lederman HM, Fivush BA. Antibody levels to diphtheria, tetanus, and rubella in infants vaccinated while on PD: a Study of the Pediatric Peritoneal Dialysis Study Consortium. Adv Perit Dial. 1997;13:297-9. PubMed 9440877 ↗
  • Leibl H, Engl W, Melamed I, Stein M, Wasserman RL, Berger M, Schiff RI. IGIV-10% Infused Intravenously And Subcutaneously To Subjects With Primary Immunodeficiency Diseases - Comparison Of Pharmacokinetic Properties. Poster presentation at AAAAI 2009.
  • Schiff RI, Leibl H, Engl W. Pharmacokinetic properties of Gammagard Liquid 10% (KIOVIG) administered intravenously and subcutaneously to patients with primary immunodeficiency diseases. Clin Exp Immunol. 154 (Suppl. 1):132, 2008
  • Wasserman RL, Melamed I, Kobrynski L, Strausbaugh SD, Stein MR, Sharkhawy M, Engl W, Leibl H, Sobolevsky L, Gelmont D, Schiff RI, Grossman WJ. Efficacy, safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immunol. 2011 Jun;31(3):323-31. doi: 10.1007/s10875-011-9512-z. Epub 2011 Mar 22. PubMed 21424824 ↗
  • Wasserman RL, Gupta S, Stein M, Rabbat CJ, Engl W, Leibl H, Yel L. Infection rates and tolerability of three different immunoglobulin administration modalities in patients with primary immunodeficiency diseases. Immunotherapy. 2022 Mar;14(4):215-224. doi: 10.2217/imt-2021-0256. Epub 2021 Dec 21. PubMed 34931880 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2007 to primary completion in Jul 2009, 20 months.

Results were first posted in Aug 2012, 3 years 1 month after primary completion. A results delay was requested in Jul 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2007
First posted
Oct 19, 2007
StartActual
Oct 3, 2007
Primary completionActual
Jul 1, 2009
CompletionActual
Sep 1, 2009
Results delay requested
Jul 27, 2010
Results first posted
Aug 23, 2012
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00546871
Responsible party
Sponsor
First posted
Oct 19, 2007
Start date
Oct 3, 2007
Primary completion
Jul 1, 2009
Completion
Sep 1, 2009
Results posted
Aug 23, 2012
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion